<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">59554</article-id><article-id pub-id-type="doi">10.7554/eLife.59554</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Tools and Resources</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Patient-specific genomics and cross-species functional analysis implicate LRP2 in hypoplastic left heart syndrome</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-191544"><name><surname>Theis</surname><given-names>Jeanne L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-190767"><name><surname>Vogler</surname><given-names>Georg</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8303-3531</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-191546"><name><surname>Missinato</surname><given-names>Maria A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9055-758X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-191557"><name><surname>Li</surname><given-names>Xing</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-191560"><name><surname>Nielsen</surname><given-names>Tanja</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-191563"><name><surname>Zeng</surname><given-names>Xin-Xin I</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2707-7759</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-191558"><name><surname>Martinez-Fernandez</surname><given-names>Almudena</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-191561"><name><surname>Walls</surname><given-names>Stanley M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-191562"><name><surname>Kervadec</surname><given-names>Anaïs</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-191876"><name><surname>Kezos</surname><given-names>James N</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-191564"><name><surname>Birker</surname><given-names>Katja</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-191565"><name><surname>Evans</surname><given-names>Jared M</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-191566"><name><surname>O'Byrne</surname><given-names>Megan M</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-191567"><name><surname>Fogarty</surname><given-names>Zachary C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5588-3216</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-191568"><name><surname>Terzic</surname><given-names>André</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-191569"><name><surname>Grossfeld</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-68346"><name><surname>Ocorr</surname><given-names>Karen</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-50294"><name><surname>Nelson</surname><given-names>Timothy J</given-names></name><email>nelson.timothy@mayo.edu</email><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-191570"><name><surname>Olson</surname><given-names>Timothy M</given-names></name><email>olson.timothy@mayo.edu</email><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-191571"><name><surname>Colas</surname><given-names>Alexandre R</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-44567"><name><surname>Bodmer</surname><given-names>Rolf</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9087-1210</contrib-id><email>rolf@sbpdiscovery.org</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Cardiovascular Genetics Research Laboratory</institution><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Development, Aging and Regeneration, Sanford Burnham Prebys Medical Discovery Institute</institution><addr-line><named-content content-type="city">La Jolla</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Division of Biomedical Statistics and Informatics, Mayo Clinic</institution><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Doctoral Degrees and Habilitations, Department of Biology, Chemistry, and Pharmacy, Freie Universität Berlin</institution><addr-line><named-content content-type="city">Berlin</named-content></addr-line><country>Germany</country></aff><aff id="aff5"><label>5</label><institution>Department of Cardiovascular Medicine, Mayo Clinic</institution><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Department of Molecular and Pharmacology and Experimental Therapeutics, Mayo Clinic</institution><addr-line><named-content content-type="city">La Jolla</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Center for Regenerative Medicine, Mayo Clinic</institution><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Mayo Clinic</institution><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution>University of California San Diego, Rady’s Hospital</institution><addr-line><named-content content-type="city">San Diego</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution>Division of General Internal Medicine, Mayo Clinic</institution><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Stainier</surname><given-names>Didier YR</given-names></name><role>Senior Editor</role><aff><institution>Max Planck Institute for Heart and Lung Research</institution><country>Germany</country></aff></contrib><contrib contrib-type="editor"><name><surname>Ebert</surname><given-names>Antje</given-names></name><role>Reviewing Editor</role><aff><institution>Department of Cardiology and Pneumology, University Medical Center Göttingen</institution><country>Germany</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="con" id="equal-contrib2"><label>‡</label><p>These authors also contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>02</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e59554</elocation-id><history><date date-type="received" iso-8601-date="2020-06-01"><day>01</day><month>06</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-09-29"><day>29</day><month>09</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Theis et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Theis et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-59554-v3.pdf"/><abstract><p>Congenital heart diseases (CHDs), including hypoplastic left heart syndrome (HLHS), are genetically complex and poorly understood. Here, a multidisciplinary platform was established to functionally evaluate novel CHD gene candidates, based on whole-genome and iPSC RNA sequencing of a HLHS family-trio. Filtering for rare variants and altered expression in proband iPSCs prioritized 10 candidates. siRNA/RNAi-mediated knockdown in healthy human iPSC-derived cardiomyocytes (hiPSC-CM) and in developing <italic>Drosophila</italic> and zebrafish hearts revealed that LDL receptor-related protein <italic>LRP2</italic> is required for cardiomyocyte proliferation and differentiation. Consistent with hypoplastic heart defects, compared to parents the proband’s iPSC-CMs exhibited reduced proliferation. Interestingly, rare, predicted-damaging LRP2 variants were enriched in a HLHS cohort; however, understanding their contribution to HLHS requires further investigation. Collectively, we have established a multi-species high-throughput platform to rapidly evaluate candidate genes and their interactions during heart development, which are crucial first steps toward deciphering oligogenic underpinnings of CHDs, including hypoplastic left hearts.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>lipoproteins</kwd><kwd>iPSC</kwd><kwd>cardiogenesis</kwd><kwd>congenital heart disease</kwd><kwd>hypoplastic left heart syndrome</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Zebrafish</kwd><kwd><italic>D. melanogaster</italic></kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome at Mayo Clinic Foundation</institution></institution-wrap></funding-source><award-id>SAN-233970</award-id><principal-award-recipient><name><surname>Colas</surname><given-names>Alexandre R</given-names></name><name><surname>Bodmer</surname><given-names>Rolf</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL054732</award-id><principal-award-recipient><name><surname>Bodmer</surname><given-names>Rolf</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Hypoplastic left heart syndrome is reflected by reduced proliferative capacity of patient iPSC-derived cardiomyocytes and requires the activity of LRP2/APOB proteins, likely in conjunction with SHH and WNT signaling pathways.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Hypoplastic left heart syndrome (HLHS) is a congenital heart disease (CHD) characterized by underdevelopment of the left ventricle, mitral and aortic valves, and aortic arch. Variable phenotypic manifestations and familial inheritance patterns, together with the numerous studies linking it to a diverse array of genes, suggest that HLHS is genetically heterogeneous and may have significant environmental contributors (<xref ref-type="bibr" rid="bib24">Elliott et al., 2003</xref>; <xref ref-type="bibr" rid="bib39">Iascone et al., 2012</xref>; <xref ref-type="bibr" rid="bib76">Theis et al., 2015a</xref>; <xref ref-type="bibr" rid="bib77">Theis et al., 2015b</xref>). In this scenario, synergistic combinations of filtering and validating approaches are necessary to prioritize candidate genes and gene variants that may affect cardiogenic pathways throughout the dynamic process of human heart development.</p><p>Although the cellular mechanisms for HLHS remain poorly characterized, a recent study reported generation of the first animal model of HLHS. Based on a digenic mechanism, mice deficient for HDAC-associated protein-encoding <italic>Sap130</italic> and protocadherin-coding <italic>Pcdha9</italic> exhibited left ventricular (LV) hypoplasia that was likely due – at least in part – to defective cardiomyocyte proliferation and differentiation, and increased cell death (<xref ref-type="bibr" rid="bib50">Liu et al., 2017</xref>). Similarly in humans, <xref ref-type="bibr" rid="bib29">Gaber et al., 2013</xref> provide evidence that HLHS-LV samples have more DNA damage and senescence with cell cycle arrest, and fewer cardiac progenitors and myocytes than controls. These observations suggest that impaired cardiomyocyte proliferation could be a mechanism contributing to HLHS pathogenesis, although pathogenic genes controlling this process in humans remain to be identified and validated. Therefore, new synergistic experimental approaches are needed to functionally evaluate gene candidates potentially involved in defective cardiogenesis to serve as a platform for probing the postulated oligogenic basis of CHDs, such as HLHS (<xref ref-type="bibr" rid="bib34">Hinton et al., 2007</xref>; <xref ref-type="bibr" rid="bib53">McBride et al., 2005</xref>).</p><p>Over the last decade, induced pluripotent stem cells (iPSCs) have provided a revolutionary experimental tool to reveal aspects of the cellular manifestations associated with disease pathogenesis (<xref ref-type="bibr" rid="bib52">Matsa et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Mercola et al., 2013</xref>; <xref ref-type="bibr" rid="bib56">Moretti et al., 2013</xref>). Progress in next-generation sequencing technology allows rapid whole-genome DNA and RNA sequencing, thereby providing access to high-resolution and personalized genetic information. However, the interpretation of patient-specific sequence variants is often challenged by uncertainty in establishing a pathogenic link between biologically relevant variant(s) and a complex disease (<xref ref-type="bibr" rid="bib15">Cooper and Shendure, 2011</xref>).</p><p>Testing numerous potential human disease-susceptibility genes in a mammalian in vivo model has been challenging because of high costs and low throughput. <italic>Drosophila</italic> with its genetic tools has emerged as the low cost, high-throughput model of choice for human candidate disease gene testing, including neurological and cardiac diseases (<xref ref-type="bibr" rid="bib26">Fink et al., 2009</xref>; <xref ref-type="bibr" rid="bib61">Ocorr et al., 2014</xref>; <xref ref-type="bibr" rid="bib72">Şentürk and Bellen, 2018</xref>; <xref ref-type="bibr" rid="bib70">Schroeder et al., 2019</xref>; <xref ref-type="bibr" rid="bib81">Vissers et al., 2020</xref>; <xref ref-type="bibr" rid="bib80">van der Harst et al., 2016</xref>). <italic>Drosophila</italic> has been established as an efficient model system to identify key genes and mechanisms critical for heart development and function that served as prototypes for vertebrate/mammalian studies, including in zebrafish and mice, due to high degree of conservation of genetic pathways and reduced genetic complexity (<xref ref-type="bibr" rid="bib10">Bodmer and Frasch, 2010</xref>), e.g. the first cardiogenic transcription factor <italic>Nkx2-5/tinman</italic>, discovered in <italic>Drosophila</italic> (<xref ref-type="bibr" rid="bib3">Azpiazu and Frasch, 1993</xref>; <xref ref-type="bibr" rid="bib8">Bodmer, 1993</xref>), marked the beginning of a molecular-genetic understanding of cardiac specification (<xref ref-type="bibr" rid="bib9">Bodmer, 1995</xref>; <xref ref-type="bibr" rid="bib17">Cripps and Olson, 2002</xref>; <xref ref-type="bibr" rid="bib5">Benson et al., 1999</xref>; <xref ref-type="bibr" rid="bib16">Cordes and Srivastava, 2009</xref>; <xref ref-type="bibr" rid="bib66">Qian and Srivastava, 2013</xref>; <xref ref-type="bibr" rid="bib43">Kathiriya et al., 2015</xref>; <xref ref-type="bibr" rid="bib25">Fahed et al., 2013</xref>).</p><p>For this study, we combined whole-genome sequencing (WGS), iPSC technology and model system validation with a family-based approach to identify and characterize novel HLHS-associated candidate genes and postulate potential mechanisms involved. This approach led us to identify LRP2 as a major regulator of cardiac cardiomyocyte proliferation of hiPSCs and heart development and maturation in both <italic>Drosophila</italic> and zebrafish. Consistent with our model system findings, burden analysis revealed that rare and predicted deleterious missense <italic>LRP2</italic> variants were enriched in HLHS patients as compared to healthy controls. Finally, we found evidence consistent with <italic>LRP2</italic> regulating cardiac proliferation and differentiation by potentially modulating growth-associated WNT, SHH, and TP53 pathways. Importantly, our integrated multidisciplinary high-throughput approach establishes a scalable and synergistic gene discovery platform to investigate potential oligogenic participants in genetically complex forms of human heart diseases.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Transcriptome and cell cycle activity are altered in HLHS patient-derived iPSCs and CMs</title><p>This study analyzed a family comprised of unrelated parents and their three offspring (‘5H’ family; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). The male proband (II.3) was diagnosed with non-syndromic HLHS by physical examination and echocardiography, which demonstrated aortic and mitral valve atresia, virtual absence of the left ventricular cavity, and severe aortic arch hypoplasia. He was born prematurely at 29 weeks gestation and underwent staged surgical palliation at 2 and 11 months of age. Conversion to a fenestrated Fontan circulation at 3 years of age failed owing to systolic and diastolic heart failure, necessitating early take-down. The patient subsequently died of multi-organ system failure. Echocardiography revealed structurally and functionally normal hearts in the proband’s mother (I.2), father (I.1) and siblings (II.1 and II.2). Maternal history is notable for four miscarriages.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Family-based iPSC characterization for HLHS.</title><p>(<bold>A</bold>) Pedigree of family 5H: proband with HLHS (black symbol), relatives without CHD (white symbols), miscarriages (gray diamonds). (<bold>B</bold>) Schematic for family-based iPSC production and characterization. (<bold>C</bold>) Whole-genome RNA sequencing identified 1401 concordantly DETs between proband and parents. (<bold>D</bold>) KEGG pathway analysis shows enrichment of DETs in TP53 pathway. (<bold>E</bold>) Heatmap of p53 signaling pathway-associated genes in probands vs parents. (<bold>F</bold>) Schematic describing EdU-incorporation assay in hiPSC-CMs. 5000 cells/well were plated in 384 well plates. After 48 hr EdU was added to the media and left incorporate for 24 hr. Cells were then fixed and stained (<bold>G</bold>) Graph representing quantification of EdU+ cardiomyocytes in HLHS 5H family-derived iPSC-CMs. ***p&lt;0.001 one-way ANOVA. (<bold>H</bold>) Representative images of iPSC-CMs derived from mother (Top) and proband (Bottom), stained for EdU, ACTN1 and DAPI. Scale bar: 50 µm. (<bold>I</bold>) Quantification of EdU-incorporation assay in 5H proband iPSC-CM upon KD of TP53 or CDKN1A. ****p&lt;0.0001, one-way ANOVA. (<bold>J</bold>) Representative images of 5H proband iPSC-CM stained for EdU and ACTN1 upon KD of TP53 or CDKN1A at day 28. Scale bar: 50 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59554-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Cell cycle activity is altered in HLHS patient-derived iPSCs and CMs.</title><p>(<bold>A</bold>) Heatmap of negative regulation of cell proliferation-associated genes from RNA-seq experiments in proband vs parents. (<bold>B</bold>) Heatmap of cell cycle arrest-associated genes. (<bold>C</bold>) Heatmap of positive regulation of apoptosis-associated genes.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59554-fig1-figsupp1-v3.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Cell cycle activity is altered in HLHS patient-derived iPSCs and CMs.</title><p>(<bold>A</bold>) Quantification of percentage of EdU+ cells in 75H and 151H iPSCs. Proband iPSCs show reduced EdU incorporation compared to the parents. **p&lt;0.01, ****p&lt;0.0001 in 75H family. <sup>##</sup>p&lt;0.01 in the151H family. One-way ANOVA. (<bold>B</bold>) Representative images of 75H family iPSCs labeled for EdU and DAPI. Of note, the yield of patient-derived iPSC was relatively low. Scale bar: 50 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59554-fig1-figsupp2-v3.tif"/></fig></fig-group><p>Patient-derived iPSCs are a valuable tool to investigate heart defects, such as those observed in HLHS (<xref ref-type="bibr" rid="bib76">Theis et al., 2015a</xref>; <xref ref-type="bibr" rid="bib36">Hrstka et al., 2017</xref>). In this study, iPSCs from the mother (I.2), father (I.1) and HLHS proband (II.3) were generated (<xref ref-type="bibr" rid="bib74">Takahashi and Yamanaka, 2006</xref>) to investigate differences in transcriptional profiles potentially associated with HLHS. Cells from the proband-parent trio were differentiated to day 25 (d25), using a cardiogenic differentiation protocol and processed for subsequent RNA sequencing (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). In this in vitro cellular context, bioinformatic analysis revealed 5104 differentially expressed transcripts (DETs) in d25 differentiated samples between proband vs. mother/father (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, Benjamini-corrected p&lt;0.001). We found that 1,401 DETs were concordantly differentially expressed between proband and both parents (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary files 1</xref>, <xref ref-type="supplementary-material" rid="supp2">2</xref>). Consistent with previous observations in HLHS fetuses (<xref ref-type="bibr" rid="bib29">Gaber et al., 2013</xref>), KEGG analysis revealed TP53 pathway enrichment (<xref ref-type="fig" rid="fig1">Figure 1D</xref>), including cell cycle inhibition (<xref ref-type="fig" rid="fig1">Figure 1E</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), consistent with cell proliferation being affected in proband cells.</p><p>To begin exploring this hypothesis, we measured cell cycle activity in proband and parent hiPSC-derived cardiomyocytes (hiPSC-CMs) using an EdU-incorporation assay (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Indeed, proband hiPSC-CMs exhibited reduced percentage of EdU-positive cells as compared to parents (<xref ref-type="fig" rid="fig1">Figure 1G,H</xref>). To further evaluate whether a potentially reduced proliferative activity is a more general phenotypic hallmark of HLHS cells, we evaluated the proliferative status of two additional HLHS family trios that were available to us from the HLHS cohort at Mayo Clinic (‘75H’, ‘151H’). Consistent with our findings with 5H family-trio cells (<xref ref-type="fig" rid="fig1">Figure 1G,H</xref>), the proband cells of families 75H and 151H also exhibited significant reduction of proliferative activity as compared to the parents using the EdU-incorporation assay (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). Given the upregulation of potent cell cycle inhibitors <italic>TP53</italic> or <italic>CDKN1A</italic> in 5H proband cells (<xref ref-type="fig" rid="fig1">Figure 1E</xref>), we tested whether impaired proliferation could involve the observed elevated <italic>TP53</italic> and/or <italic>CDKN1A</italic> mRNA levels. Indeed, siRNA-mediated knockdown (KD) of TP53 and CDKN1A in proband hiPSC-CMs significantly increased EdU incorporation as compared to siControl (<xref ref-type="fig" rid="fig1">Figure 1I,J</xref>). These findings are consistent with a CM proliferation defect observed in both HLHS fetuses (<xref ref-type="bibr" rid="bib29">Gaber et al., 2013</xref>) and a HLHS mouse model (<xref ref-type="bibr" rid="bib50">Liu et al., 2017</xref>).</p></sec><sec id="s2-2"><title>Family-based WGS, variant filtering, and transcriptional profiling identified 10 candidates</title><p>Array comparative genome hybridization ruled out a chromosomal deletion or duplication in the proband. WGS was carried out on genomic DNA samples from all five family members, based on 101 base paired-end reads that passed quality control standards; 92% of the reads mapped to the genome. After marking and filtering out duplicate reads, over 99% of the hg19 human reference genome had coverage. The average depth across the genome was 36X and an average of 91% of the gene body regions (exons, introns, and 5’ and 3’ untranslated regions) demonstrated a minimal read depth of 20 reads. WGS was performed to identify potentially pathogenic coding or regulatory single nucleotide variants (SNVs) or insertion/deletions (INDELs). First, we ruled out pathogenic variants within 42 genes comprising a CHD genetic testing panel (Invitae, San Francisco, CA). To identify novel HLHS candidate genes, WGS of the family quintet was filtered for rare de novo, recessive and loss-of-function variants with predicted impact on protein structure or expression, yielding 114 variants in 61 genes (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>,, <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). We next prioritized genes most likely to drive downstream pathways of dysregulated cardiogenesis in the HLHS proband by cross-referencing these candidate genes with 3,816 DETs identified in undifferentiated iPSC at d0 (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>) and 5,104 DETs identified at d25 differentiated cell lineages (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Ten genes harboring compound heterozygous (7), hemizygous (2), or homozygous (1) recessive variants (<xref ref-type="table" rid="table1">Table 1</xref>), absent in the unaffected siblings, were found to be differentially expressed within the HLHS proband’s iPSCs at d0 and d25: <italic>HSPG2, APOB, LRP2, PRTG, SLC9A1, SDHD, JPT1</italic>, <italic>ELF4, HS6ST2,</italic> and <italic>SIK1</italic> (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). qPCR confirmed reduced expression of these genes in proband in d25 iPSC-CM, compared to the parental cells (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). In order to explore if and how these genes could affect cardiac differentiation and/or function, alone or in combination, we employed an integrated gene discovery platform using multiple genetic model systems (see below). We consider this approach an efficient first pass evaluation of the potential roles of these genes in the heart; roles that need to be further substantiated by validation of patient-specific variants, also in a combinatorial fashion, based on the oligogenic hypothesis of CHDs.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Whole-genome and RNA sequencing identify HLHS candidate genes.</title><p>(<bold>A</bold>) An iterative, family-based variant filtering approach based on rarity, functional impact, and mode of inheritance and RNA sequencing data were used to filter for transcriptional differences yielding 10 candidate genes. Candidate genes were further tested in hiPSC-CM and in vivo model. (<bold>B</bold>) Human candidate genes and corresponding <italic>Drosophila</italic> ortholog as determined by DIOPT score (*confidence score: number of databases reporting orthology). Listed are heart phenotypes upon gene candidate KD. (<bold>C,D</bold>) Example of fly hearts heterozygous for <italic>LRP2/mgl</italic> show increased end-diastolic diameters (EDD, measured at green line in <bold>D</bold>). Wilcoxon rank sum test: ***p&lt;0.001. (<bold>E</bold>) Graph representing EdU-incorporation assay results of candidate gene KD in hiPSC-CM. KD of APOB (red bar) or LRP2 (green bar) reduced EdU incorporation. **p&lt;0.01 one-way ANOVA. (<bold>F</bold>) Representative images of hiPSC-CMs stained for EdU, ACTN1 and DAPI. Scale bar: 50 µm. (<bold>G</bold>) qPCR results of TP53 and CDKN1A in hiPSC-CM upon KD of APOB or LRP2. *p&lt;0.05 one-way ANOVA.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59554-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Identification of HLHS candidate genes from whole-genome and RNA sequencing.</title><p>An iterative, family-based variant filtering approach based on rarity, functional impact, and mode of inheritance yielded 61 candidate genes. RNA sequencing data from d0 iPSC and d25 differentiated iPSC were used to filter for transcriptional differences yielding ten candidate genes.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59554-fig2-figsupp1-v3.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Cell cycle activity is altered in HLHS patient-derived iPSCs and CMs.</title><p>qPCR of the 10 candidate genes in the ‘5H-family’ iPSC-CMs at day 25 of differentiation. Proband cells show downregulation of all 10 candidate genes compared to the mother’s cells (*) and 7/10 compared to the father’s cells (#). Data are normalized to the cells derived from the mother. ***p&lt;0.001; ****p&lt;0.0001; <sup>##</sup>p&lt;0.01; <sup>####</sup>p&lt;0.0001; n.s.: not significant. One-way ANOVA.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59554-fig2-figsupp2-v3.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Phenotypic assessment of HLHS candidate genes in <italic>Drosophila</italic> adult hearts.</title><p>(<bold>A</bold>) Schematic of the <italic>Drosophila</italic> adult heart assay. (<bold>B</bold>) Human candidate genes and corresponding <italic>Drosophila</italic> ortholog as determined by DIOPT score (*confidence score: number of databases reporting orthology). Listed are heart phenotypes upon knockdown (KD) in wild-type or NKX2-5/tin+/-heterozygous background. (<bold>C–E</bold>) RNAi-induced arrhythmicity and M-modes observed with <italic>LRP2/mgl</italic> and <italic>APOB/apolpp</italic> KD. (<bold>F–H</bold>) Heart size (EDD: end-diastolic diameter) alterations upon RNAi-KD of JPT1, HSPG2 and SDHD (also in NKX2-5/tin heterozygous background). Wilcoxon rank sum test: *p&lt;0.05, **p&lt;0.01, **p&lt;0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59554-fig2-figsupp3-v3.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title><italic>LRP2</italic> and <italic>APOB</italic> KD reduces total nuclei and affect cell cycle in hiPSC-CMs.</title><p>(<bold>A</bold>) qPCR showing KD efficiency for the 10 candidate genes in day 28 hiPSC-CM. For all the 10 genes tested, siRNAs KD efficiency is about 50%. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001, Student’s t-test. (<bold>B</bold>) Quantification of total nuclei in day 28 hiPSC-CMs transfected with siRNAs directed to ten candidate HLHS genes. <italic>LRP2</italic> and <italic>APOB</italic> KD reduce total cells number. (<bold>C</bold>) qPCR of tumor suppressors/cell cycle inhibitor genes in day 28 hiPSC-CMs upon KD of <italic>LRP2</italic> or <italic>APOB</italic>. Tumor suppressors/cell cycle inhibitors are upregulated upon <italic>LRP2/APOB</italic> KD compared to control. *p&lt;0.05, Student’s t-test. (<bold>D</bold>) qPCR of cell cycle genes in day 28 hiPSC-CMs upon KD of APOB or LRP2. Cell cycle genes are downregulated upon <italic>LRP2/APOB</italic> KD. *p&lt;0.05, Student’s t-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59554-fig2-figsupp4-v3.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Recessive Variants Identified in 10 Candidate Genes.</title></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Mode of inheritance</th><th>Functional impact</th><th>Transcript variant</th><th>Protein variant</th><th>Inheritance</th><th>Genotype in brother (II.1)</th><th>Genotype in sister (II.2)</th><th>gnomAD* MAF (%)</th><th>dbSNP ID</th></tr></thead><tbody><tr><td rowspan="3"><italic>HSPG2</italic></td><td rowspan="3">Cmpd Het</td><td>missense</td><td>c.2074G &gt; A; c.2077G &gt; A</td><td>p.V692M; p.V693M</td><td>Maternal</td><td>WT</td><td>WT</td><td>0.288</td><td>143669458</td></tr><tr><td>missense</td><td>c.326G &gt; A</td><td>p.R109Q</td><td>Paternal</td><td>Het</td><td>Het</td><td>0</td><td>773796176</td></tr><tr><td>promoter</td><td>c.-227C &gt; A</td><td/><td>Paternal</td><td>WT</td><td>WT</td><td>1.392</td><td>566166086</td></tr><tr><td rowspan="5"><italic>SLC9A1</italic></td><td rowspan="5">Cmpd Het</td><td valign="top">promoter</td><td>c.-906T &gt; C</td><td/><td>Paternal</td><td>Het</td><td>Het</td><td>1.227</td><td>114101904</td></tr><tr><td valign="top">promoter</td><td>c.-947T &gt; G</td><td/><td>Maternal</td><td>WT</td><td>WT</td><td>27.175</td><td>11588974</td></tr><tr><td valign="top">promoter</td><td>c.-1085A &gt; G</td><td/><td>Paternal</td><td>Het</td><td>Het</td><td>0.841</td><td>116299278</td></tr><tr><td>ENCODE TFBS</td><td>c.-1138C &gt; T</td><td/><td>Paternal</td><td>Het</td><td>Het</td><td>0.93</td><td>75089536</td></tr><tr><td>promoter</td><td>c.-1311G &gt; A</td><td/><td>Paternal</td><td>Het</td><td>Het</td><td>0.93</td><td>77414471</td></tr><tr><td rowspan="2"><italic>APOB</italic></td><td rowspan="2">Cmpd Het</td><td>missense</td><td>c.13441G &gt; A</td><td>p.A4481T</td><td>Maternal</td><td>WT</td><td>Het</td><td>2.475</td><td>1801695</td></tr><tr><td>missense</td><td>c.751G &gt; A</td><td>p.A251T</td><td>Paternal</td><td>Het</td><td>WT</td><td>0.071</td><td>61741625</td></tr><tr><td rowspan="2"><italic>LRP2</italic></td><td rowspan="2">Cmpd Het</td><td>missense</td><td>c.9613A &gt; G</td><td>p.N3205D</td><td>Maternal</td><td>WT</td><td>WT</td><td>0.407</td><td>35734447</td></tr><tr><td>missense</td><td>c.170C &gt; T</td><td>p.A57V</td><td>Paternal</td><td>WT</td><td>WT</td><td>0.032</td><td>115350461</td></tr><tr><td rowspan="3"><italic>SDHD</italic></td><td rowspan="3">Cmpd Het</td><td>promoter</td><td>c.-815G &gt; C; c.129+547C &gt; G</td><td/><td>Maternal</td><td>Het</td><td>WT</td><td>0.573</td><td>117661257</td></tr><tr><td>ENCODE TFBS</td><td>c.-205G &gt; A; c.66C &gt; T</td><td>p.A22A</td><td>Paternal</td><td>WT</td><td>WT</td><td>0.241</td><td>61734353</td></tr><tr><td>missense</td><td>c.34G &gt; A; c.-173C &gt; T</td><td>p.G12S</td><td>Maternal</td><td>Het</td><td>WT</td><td>0.729</td><td>34677591</td></tr><tr><td rowspan="2"><italic>PRTG</italic></td><td rowspan="2">Cmpd Het</td><td>microRNA Binding Site</td><td>c.*3501T &gt; G</td><td/><td>Paternal</td><td>Het</td><td>WT</td><td>0.739</td><td>77181316</td></tr><tr><td>microRNA Binding Site</td><td>c.*2678A &gt; G</td><td/><td>Maternal</td><td>WT</td><td>Het</td><td>0.019</td><td>756136447</td></tr><tr><td rowspan="2"><italic>HN1</italic></td><td rowspan="2">Cmpd Het</td><td>ENCODE TFBS</td><td>c.56+617C &gt; T; c.-903C &gt; T; c.-178+617C &gt; T; c.-590C &gt; T</td><td/><td>Maternal</td><td>Het</td><td>WT</td><td>3.764</td><td>117213586</td></tr><tr><td>promoter</td><td>c.-1748A &gt; C; c.-719A &gt; C; c.-486A &gt; C</td><td/><td>Paternal</td><td>WT</td><td>Het</td><td>0.816</td><td>73995795</td></tr><tr><td><italic>SIK1</italic></td><td>Hom Rec</td><td>missense</td><td>c.2087C &gt; T</td><td>p.P696L</td><td>Maternal and Paternal</td><td>WT</td><td>Het</td><td/><td valign="bottom">1256991707</td></tr><tr><td><italic>ELF4</italic></td><td>X-Linked</td><td>missense</td><td>c.1144G &gt; A</td><td>p.V382I</td><td>Maternal</td><td>WT</td><td>Het</td><td>0.025</td><td>148953158</td></tr><tr><td><italic>HS6ST2</italic></td><td>X-Linked</td><td>missense</td><td>c.948–40041G &gt; A; c.1046G &gt; A</td><td>p.R349Q</td><td>Maternal</td><td>WT</td><td>Het</td><td>0.146</td><td>201239951</td></tr></tbody></table><table-wrap-foot><fn><p>Cmpd Het, compound heterozygous; Het, heterozygous; Hom Rec, homozygous recessive; MAF, minor allele frequency; WT, wild- type.</p><p>*At study initiation the ESP database was used to set the 3% allele frequency filter. Updated frequencies are shown based on the newer gnomAD database curation which would now eliminate <italic>SLC9A1</italic> and <italic>HN1</italic> as candidate genes.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-3"><title>Knockdown of candidate gene orthologs in <italic>Drosophila</italic> heart</title><p>In order to determine whether these variants occurred within genes that could be important for cardiac differentiation in vivo, we took advantage of our established <italic>Drosophila</italic> heart development model and functional analysis tools (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>; <xref ref-type="bibr" rid="bib61">Ocorr et al., 2014</xref>). We hypothesized that genes critical for the <italic>Drosophila</italic> heart have conserved roles, also in humans, as previously observed (<xref ref-type="bibr" rid="bib9">Bodmer, 1995</xref>; <xref ref-type="bibr" rid="bib17">Cripps and Olson, 2002</xref>; <xref ref-type="bibr" rid="bib65">Qian et al., 2011</xref>). Predicted by DIOPT database (<xref ref-type="bibr" rid="bib37">Hu et al., 2011</xref>) to have orthologs in <italic>Drosophila</italic> (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), we analyzed nine genes using heart-specific RNAi-KD. By in vivo heart structure and function analysis (<xref ref-type="bibr" rid="bib26">Fink et al., 2009</xref>; <xref ref-type="bibr" rid="bib61">Ocorr et al., 2014</xref>), we found that KD of <italic>LRP2</italic> (<italic>mgl</italic>) and <italic>JPT1 (CG1943)</italic> caused dilated heart phenotypes, while KD of <italic>APOB</italic> (<italic>apolpp</italic>), a circulating lipoprotein ligand, and again <italic>LRP2</italic> (<italic>mgl</italic>), resulted in arrhythmias (<xref ref-type="fig" rid="fig2">Figure 2B–D</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>; <xref ref-type="video" rid="video1">Videos 1</xref>–<xref ref-type="video" rid="video3">3</xref>), suggesting developmental defects of cardiac structure and function.</p><media id="video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-59554-video1.mp4"><label>Video 1.</label><caption><title>Dissected adult fly heart showing rhythmic beating pattern.</title><p>Representative heart movies of dissected adult females showing arrhythmic beating pattern in APOB-RNAi (<xref ref-type="video" rid="video2">Video 2</xref>) and <italic>LRP2</italic>-RNAi (<xref ref-type="video" rid="video3">Video 3</xref>) compared to control hearts (<xref ref-type="video" rid="video1">Video 1</xref>). All movies are imaged at 140 frames/sec.</p></caption></media><media id="video2" mime-subtype="mp4" mimetype="video" xlink:href="elife-59554-video2.mp4"><label>Video 2.</label><caption><title>APOB-RNAi causes arrhythmia in dissected adult fly hearts.</title></caption></media><media id="video3" mime-subtype="mp4" mimetype="video" xlink:href="elife-59554-video3.mp4"><label>Video 3.</label><caption><title>LRP2-RNAi causes arrhythmia in dissected adult fly hearts.</title></caption></media><p>Since HLHS is likely oligogenic (<xref ref-type="bibr" rid="bib7">Blue et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Gelb and Chung, 2014</xref>), functional requirements for some genes involved in HLHS might only become apparent in combination with variants in other cardiac-relevant genes. To test this, we examined the nine candidates in the heterozygous background for <italic>tinman/NKX2-5</italic>, which in humans is well-known to contribute to a variety of CHD/HLHS manifestations (<xref ref-type="bibr" rid="bib24">Elliott et al., 2003</xref>; <xref ref-type="bibr" rid="bib36">Hrstka et al., 2017</xref>; <xref ref-type="bibr" rid="bib6">Benson, 2010</xref>; <xref ref-type="bibr" rid="bib46">Kobayashi et al., 2014</xref>). In this in vivo context, heart-specific KD of two out of nine genes, <italic>HSPG2/Perle</italic>can (<italic>trol</italic>), involved in extracellular matrix assembly (<xref ref-type="bibr" rid="bib69">Sasse et al., 2008</xref>), and Succinate dehydrogenase subunit D <italic>SDHD</italic> (<italic>SdhD</italic>) exhibited a constricted phenotype (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3G,H</xref>). These findings demonstrate that our bioinformatic candidate gene prioritization identified several conserved candidates as cardiac relevant, but further validation is necessary to begin to link them in a causal fashion to HLHS.</p></sec><sec id="s2-4"><title><italic>LRP2</italic> and <italic>APOB</italic> regulate proliferation in human iPSC-derived cardiomyocytes</title><p>Decreased proliferation of left ventricular cardiomyocytes is emerging as a phenotypic hallmark of HLHS (<xref ref-type="bibr" rid="bib50">Liu et al., 2017</xref>; <xref ref-type="bibr" rid="bib29">Gaber et al., 2013</xref>) (see also <xref ref-type="fig" rid="fig1">Figure 1G,H</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>), suggesting that cell cycle impairment may be an important contributing factor. Thus, we asked whether siRNA-mediated KD of the prioritized 10 candidate genes from the 5H family trio (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) affects proliferation of healthy, normal hiPSC-CM (<xref ref-type="bibr" rid="bib18">Cunningham et al., 2017</xref>). Remarkably, two of the genes causing cardiac abnormalities when knocked down in <italic>Drosophila</italic> (<xref ref-type="fig" rid="fig2">Figure 2B–D</xref>), <italic>LRP2</italic> and <italic>APOB</italic>, also caused a marked reduction of EdU+ hiPSC-CMs (ACTN1+) and overall hiPSC cell numbers (<xref ref-type="fig" rid="fig2">Figure 2E,F</xref> and <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A,B</xref>). Notably, we also observed an upregulation of cell cycle inhibitors and apoptosis genes (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4C</xref>), including TP53 and CDKN1A (<xref ref-type="fig" rid="fig2">Figure 2G</xref>), as well as a downregulation of cell cycle genes (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4B,C</xref>). Collectively, these data identify <italic>LRP2</italic> and <italic>APOB</italic> as modulators of cell cycle and apoptosis in hiPSC-CMs, however, further validation is necessary to link them to contributing to the developmental cardiac impairment in HLHS patients.</p></sec><sec id="s2-5"><title>Rare variant analysis in HLHS cohort reveals enrichment in <italic>LRP2</italic></title><p>In order to explore disease relevance of candidate genes functionally validated in both systems, we asked whether the frequency of rare and predicted-damaging variants in <italic>LRP2</italic> and <italic>APOB</italic> would be higher in a cohort of 130 HLHS cases compared to 861 control individuals. Remarkably, HLHS patients had a ~ 3 fold increase in the frequency of rare, predicted-damaging <italic>LRP2</italic> missense variants compared to healthy controls (10% versus 3.4%; p=0.0008) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>; <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>). Among the 13 patients who carried a <italic>LRP2</italic> variant (<xref ref-type="fig" rid="fig3">Figure 3A,B</xref>), three shared the same predicted-damaging variant (N3205D) with the 5H proband (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>). Of note, 13 of the 130 HLHS cases (including the index family proband) possessed &lt;80% of ancestral Caucasian alleles, while all controls possessed ≥80%. Four of the 13 cases had rare, predicted-damaging missense variants in <italic>LRP2</italic>. However, all assessed variants were required to be rare in all racial populations. To eliminate the potentially confounding variable of race a Caucasian-only sub-analysis was performed, resulting in a less significant p-value for rare, predicted-damaging missense variants (7.7% versus 3.4%; p=0.05). However, removal of the predicted-damaging (CADD) restriction on rare <italic>LRP2</italic> variants among Caucasians revealed significant enrichment in cases (p=0.0035), most notably in missense and intronic variants (p=0.0178 and 0.0082, respectively, <xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>). Population-based allele frequencies, CADD scores, and location of variants within functional protein binding domains, active histone marks, or transcription factor binding sites was not different between cases and controls.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Identification of LRP2 as potential HLHS candidate gene.</title><p>(<bold>A</bold>) Cohort-wide analysis of LRP2 variants shows significant enrichment for SNVs in HLHS patients compared to control populations. Variants (blue/magenta) are found throughout LRP2 protein. (<bold>B</bold>) Table listing the HLHS families carrying LRP2 variants. (<bold>C,D</bold>) qPCR of LRP2 in 5H family (<bold>C</bold>) and in 49H family (<bold>D</bold>) showing LRP2 downregulation in carrier parent and proband compared to the non-carrier parent. ****p&lt;0.0001 one-way ANOVA #p&lt;0.05 one-way ANOVA. (<bold>E</bold>) Cardiomyocyte count in zebrafish morphants at 72 hpf were significantly reduced in the ventricle. (<bold>F</bold>) Atrial cardiomyocyte number was also reduced in morphants but to a lesser extent than in ventricles. *p&lt;0.05; ****p&lt;0.0001 unpaired two-tail Student t-test. (<bold>G</bold>, top panel) embryonic fish hearts were visualized by EGFP expression in the <italic>myl7:EGFP</italic> transgenic background (green) at 72 hpf. <italic>lrp2a</italic> morphant hearts were dysmorphic and much smaller (arrow) compared to controls. (<bold>G</bold>, lower panel) <italic>myl7:H2A-mCherry</italic> transgenic background identifies cardiomyocyte nuclei used for quantifying cardiomyocytes during development in E and F. Dotted traces outline the ventricles in G. Scale bars: 30 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59554-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title><italic>lrp2a</italic> KD and CRISPR causes reduced contractility and bradycardia in zebrafish larva.</title><p>(<bold>A</bold>) Uninjected zebrafish larva, (<bold>B</bold>) <italic>lrp2a</italic> morpholinos (MO) (1 pl of 2 ng/µl) injected larva and (<bold>C</bold>) <italic>lrp2a</italic> CRISPR genome edited F0 larva all exhibit relatively normal body morphology at 72 hpf, note the pericardial edema evident in morphant and F0 mutant (arrows). Scale bar: 200 µm. (<bold>D</bold>) End-diastolic surface area and (<bold>E</bold>) End Systolic surface area in atria and ventricles determined from high-speed movies of beating hearts at 72 hpf. (<bold>F</bold>) Contractility, measured as fractional area change, was significantly reduced in ventricles from both morphants and mutants. (<bold>G</bold>) Heart period was significantly lengthened in morphants and mutant larvae. (<bold>D–G</bold>) Two doses of <italic>lrp2a</italic> MO were injected (1 pl of 1 ng/µl or 2 ng/µl). For CRISPR/Cas9 and guide RNA concentration, please see detailed information in the Materials and Methods section. One-way ANOVA, Dunnett’s multiple comparisons post hoc test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59554-fig3-figsupp1-v3.tif"/></fig></fig-group><p>In a next step, we sought to determine whether LRP2 levels might be affected in probands with rare, predicted-damaging variants in LRP2 coding sequence. We profiled <italic>LRP2</italic> transcripts levels in patient-derived iPSCs of the 5H family as well as another family, 49H, both harboring heterozygous variants with a CADD score above 24 (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), inherited from one of the parents. Interestingly, qPCR results showed that LRP2 mRNA levels were lower in the probands of both families, as well as in the parent carrying the variant (CP), compared to non-variant carrying parent (NCP) (<xref ref-type="fig" rid="fig3">Figure 3C,D</xref>). We do not know why the protein coding variants (see <xref ref-type="table" rid="table1">Table 1</xref>) are associated with reduced RNA levels in patient-derived iPSC-CMs, which we speculate may be due to reduced stability of the variant <italic>LRP2</italic> mRNA, or altered LRP2 function could feed back to reduce expression. This corroborates the idea that these LRP2 variants (N3205D and A3344T) may be causing a genetic loss-of-<italic>LRP2</italic>-function in the 5H and 49H families. However, there are likely other contributing factors besides the presence of the <italic>LRP2</italic> variants, since echocardiography excluded CHD in carrier parents.</p></sec><sec id="s2-6"><title>Zebrafish <italic>LRP2</italic> loss-of-function results in a hypoplastic ventricular phenotype</title><p>In order to evaluate the role of LRP2 during heart development in a vertebrate model, we injected a morpholino as well as sgRNA/CRISPR directed against <italic>LRP2</italic> (<italic>lrp2a</italic>) in zebrafish embryos and evaluated the effect on heart morphology and function at 72 hpf. Overall body morphology was similar for morphant and F0 CRISPR edited larva at 72 hpf, compared to controls (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A–C</xref>). Hearts from larvae with reduced <italic>lrp2a</italic> function displayed a hypoplastic phenotype with decreased CM number (<xref ref-type="fig" rid="fig3">Figure 3E–G</xref>) and dose-dependent reductions in ventricular chamber dimensions in morphants (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D,E</xref>). Loss-of-<italic>lrp2a</italic>-function also compromised ventricular contractility and caused bradycardia in both morphants and CRISPR-edited larvae (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F,G</xref>). Collectively, our data suggest that <italic>LRP2</italic> plays a crucial role during heart development by regulating cardiomyocyte generation most prominently in the ventricular chamber.</p></sec><sec id="s2-7"><title>Potential regulatory network of validated gene candidates</title><p>In order to delineate how the candidate genes testing positive in our validation systems, <italic>APOB, HS6ST2, HSPG2, JPT1, LRP2</italic>, might affect signaling homeostasis, we assembled a gene network containing these five genes and their first neighbors (as genetic and protein-protein interactions, BioGRID) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>; <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). Strikingly, in addition to TP53 pathway misregulation (<xref ref-type="fig" rid="fig1">Figure 1D–E</xref>, <xref ref-type="fig" rid="fig2">Figure 2G</xref> and <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>), all five genes were connected to WNT and SHH signaling cascades, both key regulators of cardiac differentiation and proliferation (<xref ref-type="bibr" rid="bib11">Briggs et al., 2016</xref>; <xref ref-type="bibr" rid="bib32">Gessert and Kühl, 2010</xref>; <xref ref-type="fig" rid="fig4">Figure 4A</xref>). Interestingly, RNA-seq analysis of the proband cells is consistent with this network prediction: the negative regulator of SHH pathway, <italic>PTCH1</italic>, was upregulated, while agonists of WNT signaling pathway, <italic>WNT1/3a/8a/10b</italic> and <italic>FZD10</italic> (<xref ref-type="bibr" rid="bib20">Dawson et al., 2013</xref>), were downregulated, compared to parental cells. However, genetic interaction studies in our model systems are required in order to substantiate a link between these two pathways and LRP2 (and APOB) in CM proliferation.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Potential role for SHH, WNT and LRP2 in HLHS.</title><p>(<bold>A</bold>) A gene network integrating family-centric HLHS candidate genes with heart development. ORANGE – genes with cardiac phenotypes in iPSC/<italic>Drosophila</italic> assays. YELLOW – other candidate genes with <italic>Drosophila</italic> phenotypes. RED – Genes up-regulated in proband iPSC-CMs vs. parents. BLUE – Genes downregulated downregulated in proband iPSCs vs. parents. (<bold>B,C</bold>) qPCR for FZD10, a WNT-pathway-associated gene, (<bold>B</bold>) and for PTCH1, a SHH pathway-associated gene (<bold>C</bold>) upon LRP2 KD in hiPSC-CM. **p&lt;0.01, *p&lt;0.05 Student’s t-test. (<bold>D</bold>) Quantification of EdU- incorporation assay in hiPSC-CM upon LRP2 KD in combination with BIO, a WNT inhibitor. ***or <sup>###</sup>p&lt;0.001, ****p&lt;0.0001, one-way ANOVA. (<bold>E</bold>) Representative images of hiPSC-CM stained for EdU and ACTN1. Scale bars: 50 µm. (<bold>F</bold>) Quantification of EdU-incorporation assay in hiPSC-CM upon LRP2 KD in combination with PTCH1 KD, a SHH-associated gene. ***p&lt;0.001, ****p&lt;0.0001, one-way ANOVA. (<bold>G</bold>) Representative images of hiPSC-CM stained for EdU and ACTN1. Scale bars: 50 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59554-fig4-v3.tif"/></fig><p>As a first approach, we examined whether LRP2 could regulate WNT- and/or SHH-associated genes, using healthy control hiPSC-CM. Indeed, KD of LRP2 led to reduced <italic>FZD10</italic> and increased <italic>PTCH1</italic> RNA levels (<xref ref-type="fig" rid="fig4">Figure 4B,C</xref>), although WNT1/3a/8/10a were not affected. Next, we used the WNT agonist BIO (<xref ref-type="bibr" rid="bib78">Tseng et al., 2006</xref>) and siRNA against PTCH1 (<xref ref-type="bibr" rid="bib44">Kawagishi et al., 2018</xref>) in the presence of LRP2 siRNA. We found that LRP2 KD significantly reduced both BIO- and siPTCH1-induced proliferation in hiPSC-CMs (<xref ref-type="fig" rid="fig4">Figure 4D–G</xref>), suggesting that LRP2 is required for both WNT- and SHH-regulated CM proliferation. Further experiments are required to substantiate a link between LRP2 and SHH/WNT signaling in heart growth and differentiation.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><sec id="s3-1"><title>Integrated multidisciplinary disease gene discovery platform</title><p>Unraveling the patient-specific molecular-genetic etiology of HLHS pathogenesis will improve our ability (1) to provide individual diagnostics to families and (2) to develop novel approaches to treat or (3) prevent the disease. As an important first step toward these goals, our integrated multidisciplinary approach is able to identify variants and gene functions, emanating from WGS of family trios, that are relevant for cardiac development and differentiation. Variants in these genes are proposed candidates to potentially contribute to disease etiology. As an example of our heart disease gene discovery platform, we identified <italic>LRP2</italic> as a novel candidate CHD gene with rare variants that are enriched in HLHS patients, thus generating hypotheses for further studies.</p><p>In this study, we used the powerful combination of high-throughput DNA/RNA patient sequencing coupled with high-throughput functional screening in model systems enabling to probe gene function (alone or in combination) on a wide array of cellular processes that are deployed during heart formation. For validation in model systems, we have established an integrated multi-site and multidisciplinary pipeline that systematically evaluates the functional role of genes presenting rare and deleterious variants in HLHS patients in hiPSC, <italic>Drosophila</italic> and zebrafish heart models. As a main objective – identify and functionally evaluate genes potentially associated with CHD/HLHS – our study highlights rare, predicted-damaging <italic>LRP2</italic> missense variants as 3-fold enriched in 130 HLHS patients compared to 861 controls. Validation of this gene in hiPSCs, <italic>Drosophila</italic> and zebrafish heart models demonstrated a requirement in cardiac proliferation and differentiation, and notably, systemic KD in zebrafish resulted in ventricular cardiac but not obvious skeletal muscle defects (see also <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Mutations in <italic>LRP2</italic> have been previously associated with left ventricular non-compaction (LVNC) as well as other congenital heart defects in mouse (<xref ref-type="bibr" rid="bib4">Baardman et al., 2016</xref>) and in Donnai-Barrow Syndrome in humans (<xref ref-type="bibr" rid="bib4">Baardman et al., 2016</xref>; <xref ref-type="bibr" rid="bib42">Kantarci et al., 2008</xref>). In fact, LVNC is often accompanied by other CHDs (<xref ref-type="bibr" rid="bib73">Stähli et al., 2013</xref>). However, <italic>LRP2</italic> has not previously been linked to HLHS within curated bioinformatic networks. As many top CHD gene candidates, such as <italic>Nkx2-5</italic> and <italic>Notch</italic>, <italic>LRP2</italic> could also be involved in the etiology of relatively different CHDs, such as LVNC and HLHS. This may again be due to the fact that CHDs in general and HLHS in particular are likely oligogenic and share many common factors.</p><p>One pre-requisite to reduce the knowledge gap between patient genomes and clinical phenotypes is to establish reliable/quantifiable phenotypic links between CHD/HLHS candidate genes and their role during normal cardiac development. Given that large-scale genomic studies to identify CHD-associated genes can each generate hundreds of candidates, we have demonstrated here that our cardiac phenotypical platform is able to perform high-throughput functional screening to accommodate rapid testing of a large number of genes. Although overall heart structure in flies differs from that in vertebrates, the fundamental mechanisms of heart development and function are remarkably conserved, including a common transcriptional regulatory network (<xref ref-type="bibr" rid="bib9">Bodmer, 1995</xref>; <xref ref-type="bibr" rid="bib17">Cripps and Olson, 2002</xref>), a shared protein composition (<xref ref-type="bibr" rid="bib13">Cammarato et al., 2011</xref>), as well as electrical and metabolic properties (<xref ref-type="bibr" rid="bib61">Ocorr et al., 2014</xref>; <xref ref-type="bibr" rid="bib59">Ocorr et al., 2007</xref>; <xref ref-type="bibr" rid="bib22">Diop and Bodmer, 2015</xref>). This ‘convergent biology’ approach identified <italic>LRP2</italic> as a novel HLHS candidate gene in both the in vitro and in vivo cardiac model systems, although a definite link must await further study. Importantly, variants in <italic>LRP2</italic> were not only found to be enriched in a cohort of 130 HLHS family trios, but also produced a ventricular hypoplastic phenotype in zebrafish embryos upon loss-of-<italic>lrp2a</italic>-function. Therefore, for further mechanistic understanding of complex CHD characterized by oligogenic etiologies this triple model system testing approach enables assessment of gene function combinatorically and in sensitized genetic backgrounds (e.g. <italic>tinman</italic>/NKX2-5; see <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). Furthermore, the various LRP2 coding variants can now be tested in hiPSC-CM, fish and fly models using CRISPR/Cas technologies, and evaluate whether the specific variant mimics the KD phenotype. Patient-derived proliferation-impaired hiPSC-CM harboring LRP2 variants could be ‘corrected’ to rescue the defect in a variant/patient-specific manner. Our platform could serve as a general strategy for a first evaluation of candidate genes prioritized from genomic and bioinformatic analysis, before more effort- and time-consuming follow-up studies are undertaken (e.g. <xref ref-type="bibr" rid="bib81">Vissers et al., 2020</xref>).</p></sec><sec id="s3-2"><title>A hypothetical pathogenic role for SHH, WNT, p53 and cell proliferation in HLHS</title><p>Our current understanding of the molecular-genetic causes of HLHS is very limited, despite clear genetic origins of disease (<xref ref-type="bibr" rid="bib83">Yagi et al., 2018</xref>). Past research on HLHS has yielded very few high-confidence gene candidates that may contribute to HLHS, for example, <italic>NOTCH1</italic>, <italic>NKX2-5</italic> and <italic>MYH6</italic> have been implicated with HLHS (<xref ref-type="bibr" rid="bib24">Elliott et al., 2003</xref>; <xref ref-type="bibr" rid="bib76">Theis et al., 2015a</xref>; <xref ref-type="bibr" rid="bib77">Theis et al., 2015b</xref>), but they are also associated with other CHDs.</p><p>Heart development is a complex process that involves the interaction of many pathways and tissues, and a large number of genes have been implicated in various types of CHDs (<xref ref-type="bibr" rid="bib63">Pierpont et al., 2018</xref>). The postulated oligogenic nature of HLHS is likely the result of an unfavorable combination of disease genes, and such a combination of alleles, in turn, could affect several, successive steps of heart development. This makes it extremely difficult to model the disease by single gene mutations. Current hypotheses of the etiology of HLHS include changes in cell cycle progression of myocytes, as well as altered blood flow (‘no flow – no grow’) as a consequence of defects of valves or the outflow tract (<xref ref-type="bibr" rid="bib33">Grossfeld et al., 2019</xref>; <xref ref-type="bibr" rid="bib68">Saraf et al., 2019</xref>).</p><p>Interestingly, the only mouse HLHS model to date, a digenic mutant for <italic>Sap130</italic> and <italic>pcdha9</italic> (<xref ref-type="bibr" rid="bib50">Liu et al., 2017</xref>), has a penetrance of less than 30%, indicating a profound role for subtle differences between genetic backgrounds. This mouse model suggests a separate mechanism with pcdha9 affecting aortic growth, whereas <italic>Sap130</italic> can exert a more severe HLHS-like phenotype, which might reflect a modular etiology of HLHS that separates valve and ventricular defects.</p><p>The gene network analysis that we have conducted points to the possibility that several of the prioritized candidate genes identified in the index 5H patient may have a modulatory impact on proliferation and differentiation, potentially via WNT/SHH-associated pathways (<xref ref-type="bibr" rid="bib11">Briggs et al., 2016</xref>). There is evidence that the three of the candidates with fly heart phenotypes – <italic>Trol/HSPG2, Mgl/LRP2</italic> and <italic>Apolpp/APOB</italic> – can alter WNT and SHH signaling (<xref ref-type="bibr" rid="bib14">Christ et al., 2015</xref>; <xref ref-type="bibr" rid="bib19">Datta et al., 2006</xref>), but future studies – for example genetic interaction experiments in our model systems – are needed to support their involvement. We hypothesize that a collective of likely hypomorphic genetic variants affects heart development leading to HLHS. Impaired ventricular growth could in addition be caused by changes in the p53 pathway, and our analysis of iPSC-derived cardiomyocytes suggests that p53 indeed depends on LRP2 levels. Such a multi-hit model of HLHS caused by sub-threshold hypomorphic alleles represents an attractive explanation of many CHDs.</p><p>In summary, this integrated multidisciplinary strategy of functional genomics using patient-specific iPSC combined with in vivo and human cellular model systems of functional validation has much promise in generating hypotheses, such as novel genetic pathways and potential polygenic interactions underlying CHD/HLHS. Evaluating patient-specific, complex polygenic risk factors potentially underlying HLHS will likely establish the groundwork for definitive mechanistic studies of interacting risk factors that contribute to defective cardiac development and adverse outcomes. This scalable approach promises more efficient discovery of novel CHD/HLHS gene candidates and multiple HLHS families can now be multiplexed in future diagnostic and therapeutic studies.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Genetic reagent (<italic>D. melanogaster</italic>)</td><td valign="top"><italic>Hand<sup>4.2</sup></italic>-Gal4</td><td valign="top">NA</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/16467358">16467358</ext-link></td><td valign="top">NA</td></tr><tr><td valign="top">Genetic reagent (<italic>D. melanogaster</italic>)</td><td valign="top">UAS-trol<sup>RNAi</sup></td><td valign="top">Vienna <italic>Drosophila</italic> Resource Center (VDRC)</td><td valign="top">FBst0454629</td><td valign="top">v22642</td></tr><tr><td valign="top">Genetic reagent (<italic>D. melanogaster</italic>)</td><td valign="top">UAS-CG1943<sup>RNAi</sup></td><td valign="top">Vienna <italic>Drosophila</italic> Resource Center (VDRC)</td><td valign="top">FBst0453803</td><td valign="top">v20758</td></tr><tr><td valign="top">Genetic reagent (<italic>D. melanogaster</italic>)</td><td valign="top">UAS-apolpp<sup>RNAi</sup></td><td valign="top">Vienna <italic>Drosophila</italic> Resource Center (VDRC)</td><td valign="top">FBst0470481</td><td valign="top">v6878</td></tr><tr><td valign="top">Genetic reagent (<italic>D. melanogaster</italic>)</td><td valign="top">UAS-Hs6st<sup>RNAi</sup></td><td valign="top">Vienna <italic>Drosophila</italic> Resource Center (VDRC)</td><td valign="top">FBst0464695</td><td valign="top">v42658</td></tr><tr><td valign="top">Genetic reagent (<italic>D. melanogaster</italic>)</td><td valign="top">UAS-mgl<sup>RNAi</sup></td><td valign="top">Vienna <italic>Drosophila</italic> Resource Center (VDRC)</td><td valign="top">FBst0461660</td><td valign="top">v36389</td></tr><tr><td valign="top">Genetic reagent (<italic>D. melanogaster</italic>)</td><td valign="top">UAS-Sdhd<sup>RNAi</sup></td><td valign="top">Vienna <italic>Drosophila</italic> Resource Center (VDRC)</td><td valign="top">FBst0456581</td><td valign="top">v26776</td></tr><tr><td valign="top">Genetic reagent (<italic>D. melanogaster</italic>)</td><td valign="top">UAS-Nhe2<sup>RNAi</sup></td><td valign="top">Vienna <italic>Drosophila</italic> Resource Center (VDRC)</td><td valign="top">FBst0477879</td><td valign="top">v106053</td></tr><tr><td valign="top">Genetic reagent (<italic>D. melanogaster</italic>)</td><td valign="top">UAS-Jupiter<sup>RNAi</sup></td><td valign="top">Vienna <italic>Drosophila</italic> Resource Center (VDRC)</td><td valign="top">FBst0455704</td><td valign="top">v25044</td></tr><tr><td valign="top">Genetic reagent (<italic>D. melanogaster</italic>)</td><td valign="top">UAS-Eip74EF<sup>RNAi</sup></td><td valign="top">Vienna <italic>Drosophila</italic> Resource Center (VDRC)</td><td valign="top">FBst0477129</td><td valign="top">v105301</td></tr><tr><td valign="top">Genetic reagent (<italic>D. melanogaster</italic>)</td><td valign="top">UAS-Sik2<sup>RNAi</sup></td><td valign="top">Vienna <italic>Drosophila</italic> Resource Center (VDRC)</td><td valign="top">FBst0456442</td><td valign="top">v26496</td></tr><tr><td valign="top">Genetic reagent (<italic>D. melanogaster</italic>)</td><td valign="top">mgl<sup>MI14318</sup></td><td valign="top">Bloomington <italic>Drosophila</italic> Stock Center (BDSC)</td><td valign="top">FBal0302551</td><td valign="top">BL-59689</td></tr><tr><td valign="top">Genetic reagent (<italic>D. melanogaster</italic>)</td><td valign="top">tin<sup>346</sup></td><td valign="top">NA</td><td valign="top">FBal0035787</td><td valign="top">NA</td></tr><tr><td valign="top">Strain, strain background (<italic>D. rerio</italic>)</td><td valign="top">Oregon AB wild-type</td><td valign="top"/><td valign="top"/><td valign="top">A commonly used wild-type strain</td></tr><tr><td valign="top">Strain, strain background (<italic>D. rerio</italic>)</td><td valign="top"><italic>Tg(myl7:EGFP)<sup>twu277</sup></italic></td><td valign="top">Tsai Lab, National Taiwan University</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/12950077">12950077</ext-link></td><td valign="top">A transgenic line of zebrafish labeled with heart-specific EGFP fluorescence.</td></tr><tr><td valign="top">Strain, strain background (<italic>D. rerio</italic>)</td><td valign="top"><italic>Tg(myl7:H2A-mCherry)<sup>sd12</sup></italic></td><td valign="top">Yelon Lab, University of California, San Diego</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/24075907">24075907</ext-link></td><td valign="top">A transgenic line of zebrafish specifically expressing mCherry in cardiomyocyte nuclei</td></tr><tr><td valign="top">Antibody</td><td valign="top">mouse monoclonal anti-ACTN1</td><td valign="top">Sigma</td><td valign="top">A7811</td><td valign="top">1:800</td></tr><tr><td valign="top">Antibody</td><td valign="top">donkey polyclonal anti-mouse Alexa fluor 568</td><td valign="top">Invitrogen</td><td valign="top">A10037</td><td valign="top">1:1000</td></tr><tr><td valign="top">Antibody</td><td valign="top">chicken polyclonal anti-GFP</td><td valign="top">Aves Labs</td><td valign="top">GFP-1020</td><td valign="top">1:300</td></tr><tr><td valign="top">Antibody</td><td valign="top">rabbit polyclonal abit-mCherry</td><td valign="top">Rockland</td><td valign="top">600–401 P16S</td><td valign="top">1:200</td></tr><tr><td valign="top">Antibody</td><td valign="top">donkey polyclonal anti-chicken AlexaFluor 488</td><td valign="top">Jackson ImmunoResearch</td><td valign="top">703-545-155</td><td valign="top">1:200</td></tr><tr><td valign="top">Antibody</td><td valign="top">donkey polyclonal anti-rabbit AlexaFluor 568</td><td valign="top">Invitrogen</td><td valign="top">A10042</td><td valign="top">1:200</td></tr><tr><td valign="top">Other</td><td valign="top">DAPI (iPSC) 500 mg/mL</td><td valign="top">Sigma</td><td valign="top">D9542</td><td valign="top">1:1000</td></tr><tr><td valign="top">Other</td><td valign="top">DAPI (Zebrafish) 500 mg/mL</td><td valign="top">Invitrogen</td><td valign="top">D1306</td><td valign="top">1:200</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">LRP2 siRNA</td><td valign="top">Entrez Gene ID: 4036</td><td valign="top">Dharmacon</td><td valign="top">On-Target plus, SmartPool</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">APOB siRNA</td><td valign="top">Entrez Gene ID: 338</td><td valign="top">Dharmacon</td><td valign="top">On-Target plus, SmartPool</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">PTCH1 siRNA</td><td valign="top">Entrez Gene ID: 5727</td><td valign="top">Dharmacon</td><td valign="top">On-Target plus, SmartPool</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">TP53 siRNA</td><td valign="top">Entrez Gene ID: 7157</td><td valign="top">Dharmacon</td><td valign="top">On-Target plus, SmartPool</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">CDKN1A siRNA</td><td valign="top">Entrez Gene ID: 1026</td><td valign="top">Dharmacon</td><td valign="top">On-Target plus, SmartPool</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">ELF4 siRNA</td><td valign="top">Entrez Gene ID: 2000</td><td valign="top">Dharmacon</td><td valign="top">On-Target plus, SmartPool</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">JPT1 siRNA</td><td valign="top">Entrez Gene ID: 51155</td><td valign="top">Dharmacon</td><td valign="top">On-Target plus, SmartPool</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HS6ST2 siRNA</td><td valign="top">Entrez Gene ID: 90161</td><td valign="top">Dharmacon</td><td valign="top">On-Target plus, SmartPool</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HSPG2 siRNA</td><td valign="top">Entrez Gene ID: 3339</td><td valign="top">Dharmacon</td><td valign="top">On-Target plus, SmartPool</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">PRTG siRNA</td><td valign="top">Entrez Gene ID: 283659</td><td valign="top">Dharmacon</td><td valign="top">On-Target plus, SmartPool</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">SDHD siRNA</td><td valign="top">Entrez Gene ID: 6392</td><td valign="top">Dharmacon</td><td valign="top">On-Target plus, SmartPool</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">SIK1 siRNA</td><td valign="top">Entrez Gene ID: 150094</td><td valign="top">Dharmacon</td><td valign="top">On-Target plus, SmartPool</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">SLC9A1 siRNA</td><td valign="top">Entrez Gene ID: 6548</td><td valign="top">Dharmacon</td><td valign="top">On-Target plus, SmartPool</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">CDH</td><td valign="top">Hs00170423_m1</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">characterization of the pluripotent state</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">DNMT3</td><td valign="top">Hs01003405_m1</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">characterization of the pluripotent state</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">DPPA2</td><td valign="top">Hs00414521_g1</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">characterization of the pluripotent state</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">DPPA5</td><td valign="top">Hs00988349_g1</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">characterization of the pluripotent state</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">ERAS</td><td valign="top">Hs.PT.45.4849266.g</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">characterization of the pluripotent state</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">GDF3</td><td valign="top">Hs00220998_m1</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">characterization of the pluripotent state</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">OCT-4</td><td valign="top">Hs.PT.45.14904310.g</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">characterization of the pluripotent state</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">REXO1</td><td valign="top">Hs.PT.45.923095.g</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">characterization of the pluripotent state</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">SALL4</td><td valign="top">Hs00360675_m1</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">characterization of the pluripotent state</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">TDG1</td><td valign="top">Hs02339499_g1</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">characterization of the pluripotent state</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">TERT</td><td valign="top">Hs99999022_m1</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">characterization of the pluripotent state</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">APOB</td><td valign="top">Hs.PT.56a.1973344</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">characterization of the pluripotent state</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">DHCR24</td><td valign="top">Hs.PT.56a.4561516</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">expression during guided cardiac differentiation</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">ELF4</td><td valign="top">Hs.PT.56a.25941471</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">expression during guided cardiac differentiation</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HN1</td><td valign="top">Hs.PT.58.40922463.g</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">expression during guided cardiac differentiation</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HSPG2</td><td valign="top">Hs.PT.56a.18698732</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">expression during guided cardiac differentiation</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">HS6ST2</td><td valign="top">Hs.PT.56a.1354985</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">expression during guided cardiac differentiation</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">LRP2</td><td valign="top">Hs.PT.56a.1584067</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">expression during guided cardiac differentiation</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">MYLK</td><td valign="top">Hs.PT.56a.39795491</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">expression during guided cardiac differentiation</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">PCDH11X</td><td valign="top">Hs.PT.56a.26531358</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">expression during guided cardiac differentiation</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">PRTG</td><td valign="top">custom design</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">expression during guided cardiac differentiation</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">SIK1</td><td valign="top">Hs.PT.58.2995158</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">expression during guided cardiac differentiation</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">SLC9A1</td><td valign="top">Hs.PT.58.15072523</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">expression during guided cardiac differentiation</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">SDHD</td><td valign="top">Hs.PT.58.40267655.g</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">expression during guided cardiac differentiation</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">GAPDH</td><td valign="top">Hs.PT.45.8326</td><td valign="top">IDT Integrated DNA technologies, Coralville, IA</td><td valign="top">expression during guided cardiac differentiation</td></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">EdU</td><td valign="top">Click-it Plus EdU Imaging Kit</td><td valign="top">Life Technologies</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">BIO (GSK-3 Inhibitor)</td><td valign="top"/><td valign="top">Sigma</td><td valign="top">B1686</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Prism v7 and v8</td><td valign="top"/><td valign="top">GraphPad Software</td><td valign="top"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Study subjects</title><p>Written informed consent was obtained for the index family and an HLHS cohort, under a research protocol approved by the Mayo Clinic Institutional Review Board. Cardiac anatomy was assessed by echocardiography. Candidate genes were identified and prioritized by WGS of genomic DNA and RNA sequencing of patient-specific iPSC and cardiomyocytes. For variant burden analysis, controls were obtained from the Mayo Clinic Center for Individualized Medicine’s Biobank. Methods for genomic analyses, RNA Sequencing, iPSC technology, bioinformatics and statistics are described in the Online Appendix. Data are available in NCBI SRA database (see below for SRA Accession IDs).</p></sec><sec id="s4-2"><title>Comparative genomic hybridization</title><p>To detect aneuploidy, array comparative genomic hybridization was performed using a custom 180K oligonucleotide microarray (Agilent, Santa Clara, CA), with a genome-wide functional resolution of approximately 100 kilobases. Deletions larger than 200 kilobases and duplications larger than 500 kilobases were considered clinically relevant.</p></sec><sec id="s4-3"><title>Whole-genome sequencing (WGS) and bioinformatics analyses of index family</title><p>Genomic DNA was isolated from peripheral white blood cells or saliva. WGS and variant call annotation were performed utilizing the Mayo Clinic Medical Genome Facility and Bioinformatics Core. Paired-end libraries were prepared using the TruSeq DNA v1 sample prep kit following the manufacturer’s protocol (Illumina, San Diego, CA). Each whole-genome library was loaded into four lanes of a flow cell and 101 base pair paired-end sequencing was carried out on Illumina’s HiSeq 2000 platform using TruSeq SBS sequencing kit version three and HiSeq data collection version 1.4.8 software. Reads were aligned to the hg19 reference genome using Novoalign version 2.08 (<ext-link ext-link-type="uri" xlink:href="http://novocraft.com">http://novocraft.com</ext-link>) and duplicate reads were marked using Picard (<ext-link ext-link-type="uri" xlink:href="http://picard.sourceforge.net">http://picard.sourceforge.net</ext-link>). Local realignment of INDELs and base quality score recalibration were then performed using the Genome Analysis Toolkit version 1.6–9 (GATK) (<xref ref-type="bibr" rid="bib54">McKenna et al., 2010</xref>). SNVs and INDELs were called across all samples simultaneously using GATK’s Unified Genotype with variant quality score recalibration (VQSR) (<xref ref-type="bibr" rid="bib21">DePristo et al., 2011</xref>).</p><p>Variant call format (VCF) files with SNV and INDEL calls from each family member were uploaded and analyzed using Ingenuity Variant Analysis software (QIAGEN, Redwood City, CA) where variants were functionally annotated and filtered by an iterative process. First, rare, high quality heterozygous variants were selected that (a) had a read depth of at least 10 (b) were not adjacent to a homopolymer exceeding five base pairs (c) were present in &lt;5 whole exome sequencing (WES) datasets collected from 147 individuals not affected with HLHS and (d) were present at a frequency &lt;1% (de novo, loss-of-function, CHD panel genes) or &lt;3% (compound heterozygous, hemizygous or homozygous recessive) in the Exome Variant Server (WES data from 6503 individuals, URL: <ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS">http://evs.gs.washington.edu/EVS</ext-link>) 1000 Genomes (WGS data from 1092 individuals) (<xref ref-type="bibr" rid="bib1">Abecasis et al., 2012</xref>), and/or Complete Genomics Genome (WGS data from 69 individuals) (<xref ref-type="bibr" rid="bib23">Drmanac et al., 2010</xref>). Second, functional variants were selected, defined as those that impacted a protein sequence, canonical splice site, microRNA coding sequence/binding site, enhancer region, or transcription factor binding site within a promoter validated by ENCODE chromatin immunoprecipitation experiments (<xref ref-type="bibr" rid="bib67">Raney et al., 2014</xref>). Third, using parental and sibling WGS data, rare, functional variants in the proband were then filtered for those that arose de novo or fit homozygous recessive, compound heterozygous, or X-linked recessive modes of inheritance. In addition, any inherited frameshift and start/stop codon variants were retained if they occurred in a gene intolerant to loss-of-function (pLI score &gt; 0.75).</p></sec><sec id="s4-4"><title>WGS of an HLHS cohort and unaffected controls</title><p>WGS of 130 unrelated individuals with left ventricular hypoplasia (HLH) (80% HLHS, 20%CHD with HLH) was performed utilizing the Mayo Clinic Medical Genome Facility. For the control population, 861 individuals from the Mayo Clinic Center for Individualized Medicine’s Biobank repository (<xref ref-type="bibr" rid="bib62">Olson et al., 2013</xref>) were selected based upon absence of personal or family history of CHD and underwent WGS at HudsonAlpha Institute for Biotechnology. Variant call annotation for all 991 individuals was performed by the Mayo Clinic Bioinformatics Core. Whole- genome libraries were prepared for 130 individuals with HLHS and 101 bp or 150 bp paired-end sequencing was performed on either the Illumina HiSeq 2000 (n = 56) or HiSeq 4000 (n = 74), respectively. For the 861 Biobank individuals, whole-genome libraries were prepared, and 150 base pair paired-end sequencing was carried out on the HiSeqX Ten platform. Reads from all 991 individuals were aligned to the hg38 reference genome using BWA-MEM and duplicate reads were marked using Picard. Local realignment of insertion/deletions (INDELs) and base quality score recalibration were then performed using the Genome Analysis Toolkit version 3.4 (GATK) followed by SNV/INDEL calling with Haplotype Caller and Genotype GVCFs. VerifyBAMID (<xref ref-type="bibr" rid="bib41">Jun et al., 2012</xref>) was used to estimate sample contamination. Samples with low coverage (&lt;90% of genome covered at 10X) or a high contamination estimate (FREEMIX &gt; 0.03) were excluded. A single VCF file with SNV and INDEL calls from all 991 individuals was created for subsequent statistical analysis.</p></sec><sec id="s4-5"><title>Rare variant burden analysis of <italic>LRP2</italic> and <italic>APOB</italic></title><p>WGS data from cases and controls was compared for rare variant burden of the candidate genes that have been functionally validated in both systems (<italic>LRP2, APOB</italic>) (<xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>). Genotypes with genotype quality (GQ) &lt;20 were excluded, and the resulting data was used to calculate variant call rates and Hardy-Weinberg Equilibrium (HWE) p-values. Variants with call rate &lt; 0.95 or HWE p-value&lt;1e-8 were excluded. In addition, variants were required to pass VQSR (<xref ref-type="bibr" rid="bib54">McKenna et al., 2010</xref>; <xref ref-type="bibr" rid="bib21">DePristo et al., 2011</xref>; <xref ref-type="bibr" rid="bib79">Van der Auwera et al., 2013</xref>). Variants were only included in the analysis if they had a strong predicted functional impact based on annotation information from Clinical Annotation of Variants (CAVA) (<xref ref-type="bibr" rid="bib57">Münz et al., 2015</xref>). Specifically, we included frameshift, nonsynonymous, stop-gain, and stop-loss variants, as well as variants that alter an essential splice site. We further restricted the nonsynonymous variants to include only those with Combined Annotation Dependent Depletion (CADD) scores &gt; 24 (<xref ref-type="bibr" rid="bib45">Kircher et al., 2014</xref>). Rare variants (MAF &lt;0.01 across all races) were identified based on allele frequencies in ExAC, gnomAD, and ESP (WES data from 6503 individuals, URL: <ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS">http://evs.gs.washington.edu/EVS</ext-link>) (<xref ref-type="bibr" rid="bib48">Lek et al., 2016</xref>). The gene-level, case-control association analysis was conducted using SKAT-O (<xref ref-type="bibr" rid="bib47">Lee et al., 2012</xref>). Variants were weighted using the beta(1, 25) density function of the observed MAF (the default option in SKAT) and were mapped to genes using HG38 gene coordinates from Ensembl (<xref ref-type="bibr" rid="bib28">Frankish et al., 2017</xref>). Correcting for multiple testing, the threshold for statistical significance was set at p&lt;0.025 (0.05/2 genes).</p><p>After enrichment of rare, predicted-damaging missense variants in <italic>LRP2</italic> was established, we accounted for the potential influence of race and also relaxed functional constraints. Subsequent analyses were confined to 117 individuals with HLHS possessing &gt; 80% of ancestral Caucasian alleles. All variants residing in the gene body of <italic>LRP2</italic> were included, in addition to 1000 base pairs upstream of the transcription start site. Variants were isolated and annotated in CAVA utilizing the canonical transcript of <italic>LRP2</italic> (ENST00000263816). In addition to analyzing the total number of variants spanning the gene body, SKAT-O analysis was performed separately for each type of variant in the following categories: missense, intronic, splice site region, splice region (in-frame, missense, synonymous), synonymous, 3’ untranslated region, 5’ untranslated region and 1000 base pairs upstream of the transcription start site. Independent of CAVA annotation, SKAT-O analysis was also performed on regulatory regions as determined by ChIP-Seq data from two different sources. The first analysis included variants within regions of <italic>LRP2</italic> impacted by histone modification and CTCF binding from publicly available ENCODE datasets (<xref ref-type="bibr" rid="bib58">Narayanan et al., 2017</xref>). Twenty-one human cardiovascular tissues were assessed prior to confining the analysis to fetal human heart tissue (n = 3) (<xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref>). The second analysis was confined to ENCODE ChIP-Seq data for 161 transcription factors in 91 cell types (wgEncodeRegTfbsClusteredV3 table in UCSC) (<ext-link ext-link-type="uri" xlink:href="http://genome.ucsc.edu/">http://genome.ucsc.edu/</ext-link>).</p></sec><sec id="s4-6"><title>iPSC production and spontaneous differentiation of proband/parent cells</title><p>Fibroblasts were extracted from tissue by migration onto culture plates in fibroblast medium (DMEM, 10% Fetal bovine serum (FBS), penicillin/streptomycin (P/S), all from Thermo Fisher, Waltham, MA). For the reprogramming process, 5 × 10<sup>4</sup> fibroblasts were plated and incubated overnight to allow attachment as previously described (<xref ref-type="bibr" rid="bib27">Folmes et al., 2013</xref>). On the infection day, medium was supplemented with lentivirus encoding reprogramming genes <italic>SOX2, OCT4, KLF4</italic>, and <italic>c-MYC</italic> and incubated for 12 hr. Cells were grown in fibroblast medium for 3 days prior to being passaged onto a matrigel coated plate. Once cells were attached, fibroblast medium was substituted by pluripotency-sustaining medium supplemented with 10 µM of ROCK inhibitor (TOCRIS, Bio-Techne, Minneapolis, MN) and refreshed daily until colonies appeared (3–6 weeks). Individual colonies were manually picked and expanded on matrigel coated plates in mTeSR1 medium (STEMCELL Technologies, Vancouver, CA). Approximately every 5–6 days cells were mechanically passaged onto fresh matrigel coated plates.</p><p>For spontaneous differentiation cells were treated with collagenase IV (Invitrogen, ThermoFisher) for 20 min, gently dislodged from the plate and transferred into suspension culture in ultra-low attachment 6-well plates in differentiation medium (DMEM/F12, 20% FBS, 1% glutamax, 1% non-essential amino acids, and 0.1% 2-mercaptoethanol). On day 5, floating aggregates were transferred to gelatin-coated tissue culture plates where medium was refreshed every 2 to 3 days. Cells were harvested for RNA extraction on day 25.</p></sec><sec id="s4-7"><title>iPSC characterization of proband/parent cells</title><p>For pluripotency characterization, cells were fixed in 4% paraformaldehyde for 10 min, permeabilized with 0.1% triton-X, blocked using Superblock and stained for membrane antigens TRA-1–60 (monoclonal mouse IgM 1:100), SSEA3 (rat 1:100) and transcription factor Nanog (rabbit 1:100) (all from Stemgent, Cambridge, MA). Characterization of sarcomeric proteins included staining for MLC2a (monoclonal mouse IgG 1:200, Synaptic Systems, Göttingen, Germany) and MLC2v (rabbit 1:200, Proteintech, Rosemont, IL). Secondary staining consisted of Alexa fluor 568 anti-mouse IgM or IgG, Alexa fluor 488 anti-rat and Alexa fluor 633 or 488 anti-rabbit, all used at 1:250 dilution (Molecular Probes, Thermo Fisher) (<xref ref-type="bibr" rid="bib27">Folmes et al., 2013</xref>). Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). Confocal images were acquired with a Zeiss LSM 510.</p><p>Pluripotency properties were determined in vivo using a teratoma assay. All studies including animals were approved by the Institutional Animal Care and Use Committee at Mayo Clinic. Half a million cells in 50 µl of a 1:1 solution of differentiation medium and matrigel were injected subcutaneously in each flank of an immunodeficient mouse. Tumor growth was monitored for up to 10 weeks with growing masses harvested as they reached a 1 cm<sup>3</sup> volume. Tissue was flash frozen, cryosectioned and stained using hematoxylin/eosin (<xref ref-type="bibr" rid="bib27">Folmes et al., 2013</xref>).</p><p>Electron microscopy images were acquired with a JEOL 1200 EXII transmission electron microscope. Cells were processed through fixation with 1% glutaraldehyde and 4% formaldehyde in 0.1 M phosphate buffered saline (pH 7.2), staining with lead citrate and ultramicrotome sectioning prior to imaging (<xref ref-type="bibr" rid="bib51">Martinez-Fernandez et al., 2010</xref>).</p></sec><sec id="s4-8"><title>Transcriptome profiling with RNA sequencing (RNA-seq) and bioinformatics analysis</title><p>RNA was extracted from iPSCs and differentiated cells at days 0 and 25 using a combination of Trizol and QIAGEN RNeasy mini kit columns. Sequencing library was prepared using TruSeq RNA Library Preparation Kit v2. All samples were sequenced on Illumina Hiseq 2000 at Mayo Clinic Medical Genome Facility. The following RNA-seq data analysis was performed on Dell Precision T7500 workstation which has 96 GB RAM and 20 Intel Xeon X5680 processors (3.33 GHz) and runs 64-bit Red Hat Enterprise Linux 6.3 (Kernel Linux 2.6.32–279.14.1.el6.x86_64). The alignment of short reads (50 bp) from FASTQ files was performed using Bowtie2 and Tophat2 software. All mapped reads were assembled to transcripts using Cufflinks and merged together using Cuffmerge. Differential analyses were performed between proband and parents at each time point (day 0 and day 25: d0, d25). The results from Cuffdiff were imported into a SQL database using R package CummeRbund for extracting significantly differential genes and other data manipulation. Differential genes were selected based on the default setting in Cuffdiff with adjusted p-values at 0.05 after FDR control for correcting multiple hypothesis tests and a minimum fold change of ± fold or greater relative to control lines. Bioinformatics analysis of gene expression changes was performed using available online tools to describe differential patterns between proband, mother and father. Gene functional annotation and classification was generated using the Database for Annotation, Visualization and Integrated Discovery bioinformatics module (<ext-link ext-link-type="uri" xlink:href="http://david.abcc.ncifcrf.gov">http://david.abcc.ncifcrf.gov</ext-link>). Additionally, mapping was performed using the Kyoto Encyclopedia of Genes and Genomes array tool (<ext-link ext-link-type="uri" xlink:href="http://www.kegg.jp/kegg/download/kegtools.html">http://www.kegg.jp/kegg/download/kegtools.html</ext-link>). Heat maps were generated from sorted Database for Annotation, Visualization and Integrated Discovery and Kyoto Encyclopedia of Genes and Genomes gene subsets using TIGR’s open source MeV software (<ext-link ext-link-type="uri" xlink:href="http://tm4.org/mev">http://tm4.org/mev</ext-link>). In each sample, for each mapped gene, sample data points were normalized to the mean expression across proband, father and mother and subsequently log2 transformed. Significant function groups were ranked based on statistical significance (p) from hypergeometric distribution.</p></sec><sec id="s4-9"><title>Guided cardiac differentiation</title><p>Guided differentiation was achieved using a modified version of a previously published protocol (<xref ref-type="bibr" rid="bib49">Lian et al., 2013</xref>). In brief, iPSCs cells were cultured as monolayer for two passages prior to induction. Next, they were treated with 8–12 µM Wnt activator CHIR99021 (Stemcell technologies) for 20 hr followed by 24 hr wash out period in DMEM:F12 with B27 supplement (Gibco, ThermoFisher). Medium was then refreshed and supplemented with 5 µM Wnt inhibitor IWP2 for 48 hr. Cells were maintained in DMEM:F12 plus B27 for an extra 48 hr and in DMEM:F12 plus B27 (minus insulin) thereafter. Cultures were sampled for RNA extraction before induction as well as at days 1, 3, 5, 7, 14, and 37. Beating could be observed after 7–10 days of differentiation.</p><p>hiPSCs, hiPSC-CMs, siRNA transfection, EdU assay, Immunostaining and qRT-PCR hiPSCs derived from HLHS families were plated in 384 wells coated with matrigel at 5000 cell/well density using mTeSR-1 (Stem Cell). After 3 days, EdU was added to the media and was incubated for 1 hr. Cells were fixed in 4% PFA and stained for EdU and DAPI (Invitrogen). EdU was detected using Click-it Plus EdU Imaging Kit (Life Technologies) following manufacturing directions. iPSC-CMs from 5H, 75H and 151H families and healthy hiPSC-CMs (<xref ref-type="bibr" rid="bib12">Burridge et al., 2014</xref>) at day 25 of differentiation were plated in 384 wells coated with matrigel at 5000 cells/well density in Maintenance Media (MM) (RPMI, 2% KOSR, 1% B27, 1% P/S). siRNA transfection was performed using Opti-Mem (Gibco) and Lipofectamine RNAiMAX (Gibco). siRNAs were purchased at Dharmacon and used at a final concentration of 25 nM. siRNA transfection efficiency was tested with qRT-PCR (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4A</xref>). siRNA scramble was used as control (siCTR). To test WNT-pathway interaction, cells were treated with 1 uM BIO (GSK-3 inhibitor) (Sigma B1686) for three days. Two days after transfection, 50% of media was removed and replaced with 20 µM EdU in MM media. 24 hr after, cells were fixed in 4% paraformaldehyde (PFA) and blocked in blocking buffer (10% Horse Serum, 10% Gelatin, 0.5% Triton X-100). Cells were stained with mouse monoclonal anti-α-Actinin (ACTN1) (Sigma, A7811 1:800), secondary antibody Alexa fluor 568 anti-mouse (Invitrogen, 1:1000) and DAPI (1:1000) in blocking buffer and imaged using ImageXPress microscope, (Molecular Devices) and analyzed with MetaXpress Analysis software (Molecular Devices). To obtain a cardiomyocyte proliferation index, the total number of cells positive for EdU, α-Actinin and DAPI was divided by the total number of DAPI cells and expressed as percentage. For qRT-PCR experiments, total RNA was extracted using TRIzol and chloroform. 1 ug of RNA was converted in cDNA using QuantiTect Reverse Transcription kit (QIAGEN). qRT-PCR was performed using Syber green (Biorad). Human primers sequences for qRT-PCR were obtained from Harvard Primer Bank. TP53 (Primer Bank ID: 371502118 c1), CDKN1A (Primer Bank ID: 310832423 c1), LRP2 (Primer Bank ID: 126012572 c1), FZD10 (Primer Bank ID: 314122154 c3), PTCH1 (Primer Bank ID: 134254431 c3), CCNE1 (Primer Bank ID: 339275820 c3) PCNA (Primer Bank ID: 33239449 c1), CCNB1 (Primer Bank ID: 356582356 c1), CCNB2 (Primer Bank ID: 332205979 c1), CDK1 (Primer Bank ID: 281427275 c1), CRADD (Primer Bank ID: 51988883 c1), CASP6 (Primer Bank ID: 73622127 c1), CDKN2C (Primer Bank ID: 17981697 c1), CDKN1C (Primer Bank ID: 169790898 c1), APOB (Primer Bank ID: 105990531 c1), ELF4 (Primer Bank ID: 187608766 c1), HN1(JPT1) (Primer Bank ID: 7705877a1), HS6ST2 (Primer Bank ID: 116295253 c2), HSPG2 (Primer Bank ID: 140972288 c1), PRTG (Primer Bank ID: 224500891 c2), SDHD (Primer Bank ID: 222352156 c3), SIK1 (Primer Bank ID: 116256470 c1), SLC9A1 (Primer Bank ID: 381214343 c3). GAPDH (Primer Bank ID: 378404907 c1) was used as housekeeping gene and used to normalize the data. At least three independent biological replicates were performed for each experiment.</p><p>Quantitative Real Time PCR (qRT-PCR) in iPSC qRT-PCR for pluripotency and disease-associated markers was performed in iPSC samples. RNA was extracted using a combination of Trizol and QIAGEN RNeasy mini kit columns. cDNA for pluripotency assessment was synthesized using reverse transcriptase supermix reagents (Invitrogen, Thermo Fisher). In the case of expression levels during a time course of differentiation, a Biorad (Hercules, CA) iScript synthesis kit was used. qRT-PCR was performed using pre-designed primers (see key resources table). All values were normalized to <italic>GAPDH</italic>.</p></sec><sec id="s4-10"><title><italic>Drosophila</italic> and zebrafish heart function studies</title><p><italic>Drosophila</italic> orthologs were determined using the DIOPT database (<xref ref-type="bibr" rid="bib37">Hu et al., 2011</xref>), and RNAi lines were obtained from the Vienna <italic>Drosophila</italic> Resource Center (VDRC) stock center and crossed to the heart-specific <italic>Hand<sup>4.2</sup></italic>-Gal4 driver alone or in combination with one copy of the <italic>tinman</italic> loss-of-function allele <italic>tin<sup>346</sup></italic> (<xref ref-type="bibr" rid="bib3">Azpiazu and Frasch, 1993</xref>). Fly hearts were filmed and analyzed according to standard protocol (<xref ref-type="bibr" rid="bib26">Fink et al., 2009</xref>). In zebrafish, gene expression was manipulated using standard microinjection of morpholino (MO) antisense oligonucleotides (<xref ref-type="bibr" rid="bib82">Westerfield, 1993</xref>). In addition, we performed targeted mutagenesis using CRISPR/Cas9 genome editing (<xref ref-type="bibr" rid="bib75">Talbot and Amacher, 2014</xref>; <xref ref-type="bibr" rid="bib30">Gagnon et al., 2014</xref>; <xref ref-type="bibr" rid="bib40">Irion et al., 2014</xref>), to create insertion/deletion (INDEL) mutations in the <italic>lrp2a</italic> gene (F0). Zebrafish were raised to 72 hr post fertilization (hpf), immobilized in low melt agarose and the hearts were filmed and analyzed, as for <italic>Drosophila</italic> (<xref ref-type="bibr" rid="bib26">Fink et al., 2009</xref>).</p></sec><sec id="s4-11"><title>Zebrafish husbandry</title><p>All zebrafish experiments were performed in accordance to protocols approved by IACUC. Zebrafish were maintained under standard laboratory conditions at 28.5°C. In addition to Oregon AB wild-type, the following transgenic lines were used: <italic>Tg(myl7:EGFP)<sup>twu277</sup></italic> (<xref ref-type="bibr" rid="bib38">Huang et al., 2003</xref>) and <italic>Tg(myl7:H2A-mCherry)<sup>sd12</sup></italic> (<xref ref-type="bibr" rid="bib71">Schumacher et al., 2013</xref>).</p></sec><sec id="s4-12"><title>Zebrafish semi-automated optical heartbeat analysis (SOHA)</title><p>Larval zebrafish (72 hpf) were immobilized in a small amount of low melt agarose (1.5%) and submerged in conditioned water. Beating hearts were imaged with direct immersion optics and a digital high-speed camera (up to 200 frame/s, Hamamatsu Orca Flash) to record 30 s movies; images were captured using HC Image (Hamamatsu Corp.). Cardiac function was analyzed from these high-speed movies using semi-automatic optical heartbeat analysis software (<xref ref-type="bibr" rid="bib26">Fink et al., 2009</xref>; <xref ref-type="bibr" rid="bib60">Ocorr et al., 2009</xref>), which for zebrafish quantifies heart period (R-R interval), cardiac rhythmicity, as well as chamber size and fractional area change. All hearts were imaged at room temperature (20–21°C). Statistical analyses were performed using Prism software (Graphpad). Significance was determined using two-tailed, unpaired Student t-test or one-way ANOVA and Dunnett’s multiple comparisons post hoc test as appropriate.</p></sec><sec id="s4-13"><title>Zebrafish cardiomyocyte cell counts and cardiac immunofluorescent imaging</title><p>To count cardiomyocytes, we used the expression of H2AmCherry in the nuclei (<italic>Tg(myl7:H2A-mCherry</italic>)) (<xref ref-type="bibr" rid="bib71">Schumacher et al., 2013</xref>) to qualify as an individual cell, performed the ‘Spot’ function in Imaris to distinguish individual cells in reconstructions of confocal z-stacks (<xref ref-type="bibr" rid="bib84">Zeng and Yelon, 2014</xref>; <xref ref-type="bibr" rid="bib64">Pradhan et al., 2017</xref>). To compare data sets, we used Prism software (GraphPad) to perform Student's t-test with two-tail distribution. Graphs display mean and standard deviation for each data set.</p><p>Whole-mount immunofluorescence was performed as previously described (<xref ref-type="bibr" rid="bib84">Zeng and Yelon, 2014</xref>; <xref ref-type="bibr" rid="bib64">Pradhan et al., 2017</xref>; <xref ref-type="bibr" rid="bib2">Alexander et al., 1998</xref>) (see key resources table). Confocal imaging was performed on an LSM 710 confocal microscope (Zeiss, Germany) with a 40x water objective. Exported z-stacks were processed with Imaris software (Bitplane), Zeiss Zen, and Adobe Creative Suite software (Photoshop and Illustrator 2020). All confocal images shown are projection views of partial reconstructions from multiple z-stack slices, except where noted that images are views of a single slice.</p></sec><sec id="s4-14"><title>Zebrafish CRISPR/Cas9 experiments</title><p>Detailed steps for <italic>lrp2a</italic> were previously described (<xref ref-type="bibr" rid="bib35">Hoshijima et al., 2019</xref>) and we followed IDT manufacture instruction for Complexes preparation.</p><sec id="s4-14-1"><title>crRNA:tracrRNA Duplex Preparation</title><p>Target-specific Alt-R crRNA (Dr.Cas9.LRP2A.1.AC,/AltR1/rCrC rCrUrC rGrCrU rUrArU rArUrU rCrUrC rCrArA rGrUrU rUrUrA rGrArG rCrUrA rUrGrC rU/AltR2/) and common Alt-R tracrRNA were synthesized by IDT and each RNA was dissolved in duplex buffer (IDT) as 100 μM stock solution. Stock solutions were stored at −20°C. To prepare the crRNA:tracrRNA duplex, equal volumes of 100 μM Alt-R crRNA and 100 μM Alt-R tracrRNA stock solutions were mixed together and annealed by heating followed by gradual cooling to room temperature by manufacture instruction: 95°C, 5 min on PCR machine; cool to 25°C; cool to 4°C rapidly on ice. The 50 μM crRNA:tracrRNA duplex stock solution was stored at −20°C.</p></sec><sec id="s4-14-2"><title>Preparation of crRNA:tracrRNA:Cas9 RNP Complexes</title><p>Cas9 protein (Alt-R S.p. Cas9 nuclease, v.3, IDT) was adjusted to 25 μM stock solution in 20 mM HEPES-NaOH (pH 7.5), 350 mM KCl, 20% glycerol, dispensed as 8 ul aliquots, and stored at −80°C. 25 μM crRNA:tracrRNA duplex was produced by mixing equal volumes of 50 μM crRNA:tracrRNA duplex stock and duplex buffer (IDT). We used 5 μM RNP complex. To generate 5 μM crRNA:tracrRNA:Cas9 RNP complexes: 1 μl 25 μM crRNA:tracrRNA duplex was mixed with 1 μl 25 μM Cas9 stock, 2 μl H<sub>2</sub>O, and 1 μl 0.25% phenol red solution. Prior to microinjection, the RNP complex solution was incubated at 37°C, 5 min and then placed at room temperature. Approximately, one nanoliter of 5 μM RNP complex was injected into the cytoplasm of one-cell stage embryos to generate F0 larva.</p></sec></sec><sec id="s4-15"><title>Statistical analysis</title><p>The qPCR time course gene expression data were analyzed using Generalized Linear Model (GLM) to assess the statistical significance. EdU-incorporation experiments and pTP53 staining were analyzed with GraphPad Prism 8. For both, p&lt;0.05 was considered significant. All statistical analysis for iPSC-derived cardiomyocytes were performed using GraphPad Prism version 8.0 (GraphPad Software, San Diego CA, USA). Statistical significance was analyzed by unpaired Student’s <italic>t</italic>-test, and one-way ANOVA and shown as mean ± SEM. P-values were considered significant when p&lt;0.05.</p></sec><sec id="s4-16"><title>Study limitations</title><p>HLHS candidate gene selection was based on in silico predictive algorithms to filter for functional coding and regulatory variants. Our WGS filtering strategy, designed to identify major-effect de novo, recessive and loss-of-function variants, did not include consideration of inherited, incompletely penetrant, autosomal dominant variants in other genes. The potential race-specific differences in <italic>LRP2</italic> variants require further study. Differential gene expression, which was functionally validated as a powerful filter for candidate variant prioritization, excluded functional variants that do not alter gene expression. The validating KD modeling systems are justified insofar as all 10 prioritized candidate genes harbored recessive alleles inherited from the proband’s unaffected parents, implicating a loss-of-function mechanism is likely in most cases. Not all human genes are conserved in <italic>Drosophila</italic>, but ~ 80% of disease-causing human genes have fly orthologs. While structural differences exist between hiPSC-CM, <italic>Drosophila</italic> and zebrafish hearts and human newborn cardiomyocytes, our combinatorial approach allows to uncover testable gene networks and interactions that is not feasible in mammalian model systems.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors acknowledge the generous support from the Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome and the Medical Genome Facility Sequencing Core and Biobank within the Mayo Clinic Center for Individualized Medicine, Rochester, MN. We gratefully acknowledge the patients and families who participated in this study. We thank Sean Spearing, Prashila Amatya, Marco Tamayo and Bosco Trinh for excellent technical assistance.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Formal analysis, Investigation, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Investigation, Visualization</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con11"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con12"><p>Data curation, Software, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con13"><p>Data curation, Software, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con14"><p>Data curation, Software, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Resources, Supervision, Project administration</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Resources, Supervision, Investigation</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Software, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Resources, Formal analysis, Supervision, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con21"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Human subjects: Written informed consent was obtained for the index family and an HLHS cohort, under a research protocol approved by the Mayo Clinic Institutional Review Board (11-000114 &quot;Genetic Investigations in Hypoplastic Left Heart Syndrome&quot;).</p></fn><fn fn-type="other" id="fn2"><p>Animal experimentation: SBP has retained the services of a veterinarian who is a diplomat of the American College of Laboratory Animal Medicine. Close contact with Animal Facility personnel is maintained through telephone calls and on-campus visits once a week. This person is a member of the Institute's Animal Care and Use Committee (IACUC)and attends monthly meetings. This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to the Institute's Animal Care and Use Program, which is accredited by AAALAC International, and a Multiple Project Assurance A3053-1 is on file in the OLAW, DHHS. The protocol was approved by SBP IACUC (Permit Number: 19-087). Animals are euthanized after filming hearts by an overdose of anesthetic (3-aminobenzoic acid ethyl ester (MS-222)) at 250-300 mg/L.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Differentially expressed genes between proband and parental 25 day old iPSC-derived cardiomyocytes.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59554-supp1-v3.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Gene function enrichment analysis for differentially expressed transcripts at day 25.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59554-supp2-v3.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Recessive and dominant genotypes identified in index case.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59554-supp3-v3.xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Differentially expressed genes between proband and parental 0 day old iPSCs.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59554-supp4-v3.xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Interactome of prioritized HLHS candidate genes.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59554-supp5-v3.xlsx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>SKAT-O Analysis of 2 prioritized candidate genes in cases and controls.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59554-supp6-v3.xlsx"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>Rare, predicted-damaging LRP2 missense variants in cases and controls (CADD&gt;24).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59554-supp7-v3.xlsx"/></supplementary-material><supplementary-material id="supp8"><label>Supplementary file 8.</label><caption><title>Case-Control Association Analysis of Rare Variants in LRP2.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-59554-supp8-v3.pdf"/></supplementary-material><supplementary-material id="supp9"><label>Supplementary file 9.</label><caption><title>ENCODE Datasets.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59554-supp9-v3.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-59554-transrepform-v3.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Sequencing data are deposited in the NCBI Sequence Read Archive (SRA) database with accession numbers: SRS1417684 (proband iPSCs), SRS1417685 (paternal iPSCs), SRS1417686 (maternal iPSCs), SRS1417695 (proband d25 differentiated cells), SRS1417696 (paternal d25 differentiated cells), SRS1417714 (maternal d25 differentiated cells).</p><p>The following previously published dataset was used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Mayo Clinic</collab></person-group><year iso-8601-date="2017">2017</year><data-title>IPS Cells in Hypoplastic Left Heart Syndrome</data-title><source>NCBI Sequence Read Archive</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/sra/SRS1417684">SRX1736972</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abecasis</surname> <given-names>GR</given-names></name><name><surname>Auton</surname> <given-names>A</given-names></name><name><surname>Brooks</surname> <given-names>LD</given-names></name><name><surname>DePristo</surname> <given-names>MA</given-names></name><name><surname>Durbin</surname> <given-names>RM</given-names></name><name><surname>Handsaker</surname> <given-names>RE</given-names></name><name><surname>Kang</surname> <given-names>HM</given-names></name><name><surname>Marth</surname> <given-names>GT</given-names></name><name><surname>McVean</surname> <given-names>GA</given-names></name><collab>1000 Genomes Project Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>An integrated map of genetic variation from 1,092 human genomes</article-title><source>Nature</source><volume>491</volume><fpage>56</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/nature11632</pub-id><pub-id pub-id-type="pmid">23128226</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname> <given-names>J</given-names></name><name><surname>Stainier</surname> <given-names>DYR</given-names></name><name><surname>Yelon</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Screening mosaic F1 females for mutations affecting zebrafish heart induction and patterning</article-title><source>Developmental Genetics</source><volume>22</volume><fpage>288</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1520-6408(1998)22:3&lt;288::AID-DVG10&gt;3.0.CO;2-2</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azpiazu</surname> <given-names>N</given-names></name><name><surname>Frasch</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Tinman and bagpipe: two homeo box genes that determine cell fates in the dorsal mesoderm of <italic>Drosophila</italic></article-title><source>Genes &amp; Development</source><volume>7</volume><fpage>1325</fpage><lpage>1340</lpage><pub-id pub-id-type="doi">10.1101/gad.7.7b.1325</pub-id><pub-id pub-id-type="pmid">8101173</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baardman</surname> <given-names>ME</given-names></name><name><surname>Zwier</surname> <given-names>MV</given-names></name><name><surname>Wisse</surname> <given-names>LJ</given-names></name><name><surname>Gittenberger-de Groot</surname> <given-names>AC</given-names></name><name><surname>Kerstjens-Frederikse</surname> <given-names>WS</given-names></name><name><surname>Hofstra</surname> <given-names>RM</given-names></name><name><surname>Jurdzinski</surname> <given-names>A</given-names></name><name><surname>Hierck</surname> <given-names>BP</given-names></name><name><surname>Jongbloed</surname> <given-names>MR</given-names></name><name><surname>Berger</surname> <given-names>RM</given-names></name><name><surname>Plösch</surname> <given-names>T</given-names></name><name><surname>DeRuiter</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Common arterial trunk and ventricular non-compaction in <italic>Lrp2</italic> knockout mice indicate a crucial role of <italic>LRP2</italic> in cardiac development</article-title><source>Disease Models &amp; Mechanisms</source><volume>9</volume><fpage>413</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1242/dmm.022053</pub-id><pub-id pub-id-type="pmid">26822476</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benson</surname> <given-names>DW</given-names></name><name><surname>Silberbach</surname> <given-names>GM</given-names></name><name><surname>Kavanaugh-McHugh</surname> <given-names>A</given-names></name><name><surname>Cottrill</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Riggs</surname> <given-names>S</given-names></name><name><surname>Smalls</surname> <given-names>O</given-names></name><name><surname>Johnson</surname> <given-names>MC</given-names></name><name><surname>Watson</surname> <given-names>MS</given-names></name><name><surname>Seidman</surname> <given-names>JG</given-names></name><name><surname>Seidman</surname> <given-names>CE</given-names></name><name><surname>Plowden</surname> <given-names>J</given-names></name><name><surname>Kugler</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways</article-title><source>Journal of Clinical Investigation</source><volume>104</volume><fpage>1567</fpage><lpage>1573</lpage><pub-id pub-id-type="doi">10.1172/JCI8154</pub-id><pub-id pub-id-type="pmid">10587520</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benson</surname> <given-names>DW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Genetic origins of pediatric heart disease</article-title><source>Pediatric Cardiology</source><volume>31</volume><fpage>422</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1007/s00246-009-9607-y</pub-id><pub-id pub-id-type="pmid">20033147</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blue</surname> <given-names>GM</given-names></name><name><surname>Kirk</surname> <given-names>EP</given-names></name><name><surname>Giannoulatou</surname> <given-names>E</given-names></name><name><surname>Sholler</surname> <given-names>GF</given-names></name><name><surname>Dunwoodie</surname> <given-names>SL</given-names></name><name><surname>Harvey</surname> <given-names>RP</given-names></name><name><surname>Winlaw</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Advances in the genetics of congenital heart Disease: A Clinician's Guide</article-title><source>Journal of the American College of Cardiology</source><volume>69</volume><fpage>859</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2016.11.060</pub-id><pub-id pub-id-type="pmid">28209227</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodmer</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>The gene tinman is required for specification of the heart and visceral muscles in <italic>Drosophila</italic></article-title><source>Development</source><volume>118</volume><fpage>719</fpage><lpage>729</lpage><pub-id pub-id-type="pmid">7915669</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodmer</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Heart development in <italic>Drosophila</italic> and its relationship to vertebrates</article-title><source>Trends in Cardiovascular Medicine</source><volume>5</volume><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/1050-1738(94)00032-Q</pub-id><pub-id pub-id-type="pmid">21232234</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bodmer</surname> <given-names>R</given-names></name><name><surname>Frasch</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><chapter-title>Development and aging of the <italic>Drosophila</italic> heart</chapter-title><person-group person-group-type="editor"><name><surname>Harvey</surname> <given-names>N. R. R</given-names></name></person-group><source>Heart Development and Regeneration</source><publisher-name>Elsevier</publisher-name><fpage>47</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/C2009-1-62569-7</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briggs</surname> <given-names>LE</given-names></name><name><surname>Burns</surname> <given-names>TA</given-names></name><name><surname>Lockhart</surname> <given-names>MM</given-names></name><name><surname>Phelps</surname> <given-names>AL</given-names></name><name><surname>Van den Hoff</surname> <given-names>MJ</given-names></name><name><surname>Wessels</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Wnt/β-catenin and sonic hedgehog pathways interact in the regulation of the development of the dorsal mesenchymal protrusion</article-title><source>Developmental Dynamics</source><volume>245</volume><fpage>103</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1002/dvdy.24339</pub-id><pub-id pub-id-type="pmid">26297872</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burridge</surname> <given-names>PW</given-names></name><name><surname>Matsa</surname> <given-names>E</given-names></name><name><surname>Shukla</surname> <given-names>P</given-names></name><name><surname>Lin</surname> <given-names>ZC</given-names></name><name><surname>Churko</surname> <given-names>JM</given-names></name><name><surname>Ebert</surname> <given-names>AD</given-names></name><name><surname>Lan</surname> <given-names>F</given-names></name><name><surname>Diecke</surname> <given-names>S</given-names></name><name><surname>Huber</surname> <given-names>B</given-names></name><name><surname>Mordwinkin</surname> <given-names>NM</given-names></name><name><surname>Plews</surname> <given-names>JR</given-names></name><name><surname>Abilez</surname> <given-names>OJ</given-names></name><name><surname>Cui</surname> <given-names>B</given-names></name><name><surname>Gold</surname> <given-names>JD</given-names></name><name><surname>Wu</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Chemically defined generation of human cardiomyocytes</article-title><source>Nature Methods</source><volume>11</volume><fpage>855</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2999</pub-id><pub-id pub-id-type="pmid">24930130</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cammarato</surname> <given-names>A</given-names></name><name><surname>Ahrens</surname> <given-names>CH</given-names></name><name><surname>Alayari</surname> <given-names>NN</given-names></name><name><surname>Qeli</surname> <given-names>E</given-names></name><name><surname>Rucker</surname> <given-names>J</given-names></name><name><surname>Reedy</surname> <given-names>MC</given-names></name><name><surname>Zmasek</surname> <given-names>CM</given-names></name><name><surname>Gucek</surname> <given-names>M</given-names></name><name><surname>Cole</surname> <given-names>RN</given-names></name><name><surname>Van Eyk</surname> <given-names>JE</given-names></name><name><surname>Bodmer</surname> <given-names>R</given-names></name><name><surname>O'Rourke</surname> <given-names>B</given-names></name><name><surname>Bernstein</surname> <given-names>SI</given-names></name><name><surname>Foster</surname> <given-names>DB</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A mighty small heart: the cardiac proteome of adult <italic>Drosophila melanogaster</italic></article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e18497</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0018497</pub-id><pub-id pub-id-type="pmid">21541028</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christ</surname> <given-names>A</given-names></name><name><surname>Christa</surname> <given-names>A</given-names></name><name><surname>Klippert</surname> <given-names>J</given-names></name><name><surname>Eule</surname> <given-names>JC</given-names></name><name><surname>Bachmann</surname> <given-names>S</given-names></name><name><surname>Wallace</surname> <given-names>VA</given-names></name><name><surname>Hammes</surname> <given-names>A</given-names></name><name><surname>Willnow</surname> <given-names>TE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>LRP2 acts as SHH clearance receptor to protect the retinal margin from mitogenic stimuli</article-title><source>Developmental Cell</source><volume>35</volume><fpage>36</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2015.09.001</pub-id><pub-id pub-id-type="pmid">26439398</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname> <given-names>GM</given-names></name><name><surname>Shendure</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Needles in stacks of needles: finding disease-causal variants in a wealth of genomic data</article-title><source>Nature Reviews Genetics</source><volume>12</volume><fpage>628</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1038/nrg3046</pub-id><pub-id pub-id-type="pmid">21850043</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordes</surname> <given-names>KR</given-names></name><name><surname>Srivastava</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>MicroRNA regulation of cardiovascular development</article-title><source>Circulation Research</source><volume>104</volume><fpage>724</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.192872</pub-id><pub-id pub-id-type="pmid">19325160</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cripps</surname> <given-names>RM</given-names></name><name><surname>Olson</surname> <given-names>EN</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Control of cardiac development by an evolutionarily conserved transcriptional network</article-title><source>Developmental Biology</source><volume>246</volume><fpage>14</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1006/dbio.2002.0666</pub-id><pub-id pub-id-type="pmid">12027431</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname> <given-names>TJ</given-names></name><name><surname>Yu</surname> <given-names>MS</given-names></name><name><surname>McKeithan</surname> <given-names>WL</given-names></name><name><surname>Spiering</surname> <given-names>S</given-names></name><name><surname>Carrette</surname> <given-names>F</given-names></name><name><surname>Huang</surname> <given-names>CT</given-names></name><name><surname>Bushway</surname> <given-names>PJ</given-names></name><name><surname>Tierney</surname> <given-names>M</given-names></name><name><surname>Albini</surname> <given-names>S</given-names></name><name><surname>Giacca</surname> <given-names>M</given-names></name><name><surname>Mano</surname> <given-names>M</given-names></name><name><surname>Puri</surname> <given-names>PL</given-names></name><name><surname>Sacco</surname> <given-names>A</given-names></name><name><surname>Ruiz-Lozano</surname> <given-names>P</given-names></name><name><surname>Riou</surname> <given-names>JF</given-names></name><name><surname>Umbhauer</surname> <given-names>M</given-names></name><name><surname>Duester</surname> <given-names>G</given-names></name><name><surname>Mercola</surname> <given-names>M</given-names></name><name><surname>Colas</surname> <given-names>AR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Id genes are essential for early heart formation</article-title><source>Genes &amp; Development</source><volume>31</volume><fpage>1325</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1101/gad.300400.117</pub-id><pub-id pub-id-type="pmid">28794185</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datta</surname> <given-names>M</given-names></name><name><surname>Hernandez</surname> <given-names>A</given-names></name><name><surname>Schlicht</surname> <given-names>M</given-names></name><name><surname>Kahler</surname> <given-names>A</given-names></name><name><surname>DeGueme</surname> <given-names>A</given-names></name><name><surname>Dhir</surname> <given-names>R</given-names></name><name><surname>Shah</surname> <given-names>R</given-names></name><name><surname>Farach-Carson</surname> <given-names>C</given-names></name><name><surname>Barrett</surname> <given-names>A</given-names></name><name><surname>Datta</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway</article-title><source>Molecular Cancer</source><volume>5</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.1186/1476-4598-5-9</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname> <given-names>K</given-names></name><name><surname>Aflaki</surname> <given-names>M</given-names></name><name><surname>Nattel</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Role of the Wnt-Frizzled system in cardiac pathophysiology: a rapidly developing, poorly understood area with enormous potential</article-title><source>The Journal of Physiology</source><volume>591</volume><fpage>1409</fpage><lpage>1432</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2012.235382</pub-id><pub-id pub-id-type="pmid">23207593</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DePristo</surname> <given-names>MA</given-names></name><name><surname>Banks</surname> <given-names>E</given-names></name><name><surname>Poplin</surname> <given-names>R</given-names></name><name><surname>Garimella</surname> <given-names>KV</given-names></name><name><surname>Maguire</surname> <given-names>JR</given-names></name><name><surname>Hartl</surname> <given-names>C</given-names></name><name><surname>Philippakis</surname> <given-names>AA</given-names></name><name><surname>del Angel</surname> <given-names>G</given-names></name><name><surname>Rivas</surname> <given-names>MA</given-names></name><name><surname>Hanna</surname> <given-names>M</given-names></name><name><surname>McKenna</surname> <given-names>A</given-names></name><name><surname>Fennell</surname> <given-names>TJ</given-names></name><name><surname>Kernytsky</surname> <given-names>AM</given-names></name><name><surname>Sivachenko</surname> <given-names>AY</given-names></name><name><surname>Cibulskis</surname> <given-names>K</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A framework for variation discovery and genotyping using next-generation DNA sequencing data</article-title><source>Nature Genetics</source><volume>43</volume><fpage>491</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1038/ng.806</pub-id><pub-id pub-id-type="pmid">21478889</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diop</surname> <given-names>SB</given-names></name><name><surname>Bodmer</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Gaining insights into diabetic cardiomyopathy from <italic>Drosophila</italic></article-title><source>Trends in Endocrinology &amp; Metabolism</source><volume>26</volume><fpage>618</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2015.09.009</pub-id><pub-id pub-id-type="pmid">26482877</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drmanac</surname> <given-names>R</given-names></name><name><surname>Sparks</surname> <given-names>AB</given-names></name><name><surname>Callow</surname> <given-names>MJ</given-names></name><name><surname>Halpern</surname> <given-names>AL</given-names></name><name><surname>Burns</surname> <given-names>NL</given-names></name><name><surname>Kermani</surname> <given-names>BG</given-names></name><name><surname>Carnevali</surname> <given-names>P</given-names></name><name><surname>Nazarenko</surname> <given-names>I</given-names></name><name><surname>Nilsen</surname> <given-names>GB</given-names></name><name><surname>Yeung</surname> <given-names>G</given-names></name><name><surname>Dahl</surname> <given-names>F</given-names></name><name><surname>Fernandez</surname> <given-names>A</given-names></name><name><surname>Staker</surname> <given-names>B</given-names></name><name><surname>Pant</surname> <given-names>KP</given-names></name><name><surname>Baccash</surname> <given-names>J</given-names></name><name><surname>Borcherding</surname> <given-names>AP</given-names></name><name><surname>Brownley</surname> <given-names>A</given-names></name><name><surname>Cedeno</surname> <given-names>R</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Chernikoff</surname> <given-names>D</given-names></name><name><surname>Cheung</surname> <given-names>A</given-names></name><name><surname>Chirita</surname> <given-names>R</given-names></name><name><surname>Curson</surname> <given-names>B</given-names></name><name><surname>Ebert</surname> <given-names>JC</given-names></name><name><surname>Hacker</surname> <given-names>CR</given-names></name><name><surname>Hartlage</surname> <given-names>R</given-names></name><name><surname>Hauser</surname> <given-names>B</given-names></name><name><surname>Huang</surname> <given-names>S</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Karpinchyk</surname> <given-names>V</given-names></name><name><surname>Koenig</surname> <given-names>M</given-names></name><name><surname>Kong</surname> <given-names>C</given-names></name><name><surname>Landers</surname> <given-names>T</given-names></name><name><surname>Le</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>McBride</surname> <given-names>CE</given-names></name><name><surname>Morenzoni</surname> <given-names>M</given-names></name><name><surname>Morey</surname> <given-names>RE</given-names></name><name><surname>Mutch</surname> <given-names>K</given-names></name><name><surname>Perazich</surname> <given-names>H</given-names></name><name><surname>Perry</surname> <given-names>K</given-names></name><name><surname>Peters</surname> <given-names>BA</given-names></name><name><surname>Peterson</surname> <given-names>J</given-names></name><name><surname>Pethiyagoda</surname> <given-names>CL</given-names></name><name><surname>Pothuraju</surname> <given-names>K</given-names></name><name><surname>Richter</surname> <given-names>C</given-names></name><name><surname>Rosenbaum</surname> <given-names>AM</given-names></name><name><surname>Roy</surname> <given-names>S</given-names></name><name><surname>Shafto</surname> <given-names>J</given-names></name><name><surname>Sharanhovich</surname> <given-names>U</given-names></name><name><surname>Shannon</surname> <given-names>KW</given-names></name><name><surname>Sheppy</surname> <given-names>CG</given-names></name><name><surname>Sun</surname> <given-names>M</given-names></name><name><surname>Thakuria</surname> <given-names>JV</given-names></name><name><surname>Tran</surname> <given-names>A</given-names></name><name><surname>Vu</surname> <given-names>D</given-names></name><name><surname>Zaranek</surname> <given-names>AW</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Drmanac</surname> <given-names>S</given-names></name><name><surname>Oliphant</surname> <given-names>AR</given-names></name><name><surname>Banyai</surname> <given-names>WC</given-names></name><name><surname>Martin</surname> <given-names>B</given-names></name><name><surname>Ballinger</surname> <given-names>DG</given-names></name><name><surname>Church</surname> <given-names>GM</given-names></name><name><surname>Reid</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays</article-title><source>Science</source><volume>327</volume><fpage>78</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1126/science.1181498</pub-id><pub-id pub-id-type="pmid">19892942</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname> <given-names>DA</given-names></name><name><surname>Kirk</surname> <given-names>EP</given-names></name><name><surname>Yeoh</surname> <given-names>T</given-names></name><name><surname>Chandar</surname> <given-names>S</given-names></name><name><surname>McKenzie</surname> <given-names>F</given-names></name><name><surname>Taylor</surname> <given-names>P</given-names></name><name><surname>Grossfeld</surname> <given-names>P</given-names></name><name><surname>Fatkin</surname> <given-names>D</given-names></name><name><surname>Jones</surname> <given-names>O</given-names></name><name><surname>Hayes</surname> <given-names>P</given-names></name><name><surname>Feneley</surname> <given-names>M</given-names></name><name><surname>Harvey</surname> <given-names>RP</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cardiac homeobox gene NKX2-5 mutations and congenital heart disease: associations with atrial septal defect and hypoplastic left heart syndrome</article-title><source>Journal of the American College of Cardiology</source><volume>41</volume><fpage>2072</fpage><lpage>2076</lpage><pub-id pub-id-type="doi">10.1016/s0735-1097(03)00420-0</pub-id><pub-id pub-id-type="pmid">12798584</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahed</surname> <given-names>AC</given-names></name><name><surname>Gelb</surname> <given-names>BD</given-names></name><name><surname>Seidman</surname> <given-names>JG</given-names></name><name><surname>Seidman</surname> <given-names>CE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genetics of congenital heart disease: the glass half empty</article-title><source>Circulation Research</source><volume>112</volume><elocation-id>e001746</elocation-id><pub-id pub-id-type="doi">10.1161/CIRCGENETICS.117.001746</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fink</surname> <given-names>M</given-names></name><name><surname>Callol-Massot</surname> <given-names>C</given-names></name><name><surname>Chu</surname> <given-names>A</given-names></name><name><surname>Ruiz-Lozano</surname> <given-names>P</given-names></name><name><surname>Belmonte</surname> <given-names>JCI</given-names></name><name><surname>Giles</surname> <given-names>W</given-names></name><name><surname>Bodmer</surname> <given-names>R</given-names></name><name><surname>Ocorr</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A new method for detection and quantification of heartbeat parameters in <italic>Drosophila</italic>, zebrafish, and embryonic mouse hearts</article-title><source>BioTechniques</source><volume>46</volume><fpage>101</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.2144/000113078</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folmes</surname> <given-names>CD</given-names></name><name><surname>Martinez-Fernandez</surname> <given-names>A</given-names></name><name><surname>Perales-Clemente</surname> <given-names>E</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>McDonald</surname> <given-names>A</given-names></name><name><surname>Oglesbee</surname> <given-names>D</given-names></name><name><surname>Hrstka</surname> <given-names>SC</given-names></name><name><surname>Perez-Terzic</surname> <given-names>C</given-names></name><name><surname>Terzic</surname> <given-names>A</given-names></name><name><surname>Nelson</surname> <given-names>TJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Disease-causing mitochondrial heteroplasmy segregated within induced pluripotent stem cell clones derived from a patient with MELAS</article-title><source>Stem Cells</source><volume>31</volume><fpage>1298</fpage><lpage>1308</lpage><pub-id pub-id-type="doi">10.1002/stem.1389</pub-id><pub-id pub-id-type="pmid">23553816</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frankish</surname> <given-names>A</given-names></name><name><surname>Vullo</surname> <given-names>A</given-names></name><name><surname>Zadissa</surname> <given-names>A</given-names></name><name><surname>Yates</surname> <given-names>A</given-names></name><name><surname>Thormann</surname> <given-names>A</given-names></name><name><surname>Parker</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ensembl 2018</article-title><source>Nucleic Acids Research</source><volume>46</volume><elocation-id>gkx1098</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkx1098</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaber</surname> <given-names>N</given-names></name><name><surname>Gagliardi</surname> <given-names>M</given-names></name><name><surname>Patel</surname> <given-names>P</given-names></name><name><surname>Kinnear</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Chitayat</surname> <given-names>D</given-names></name><name><surname>Shannon</surname> <given-names>P</given-names></name><name><surname>Jaeggi</surname> <given-names>E</given-names></name><name><surname>Tabori</surname> <given-names>U</given-names></name><name><surname>Keller</surname> <given-names>G</given-names></name><name><surname>Mital</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Fetal reprogramming and senescence in hypoplastic left heart syndrome and in human pluripotent stem cells during cardiac differentiation</article-title><source>The American Journal of Pathology</source><volume>183</volume><fpage>720</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2013.05.022</pub-id><pub-id pub-id-type="pmid">23871585</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagnon</surname> <given-names>JA</given-names></name><name><surname>Valen</surname> <given-names>E</given-names></name><name><surname>Thyme</surname> <given-names>SB</given-names></name><name><surname>Huang</surname> <given-names>P</given-names></name><name><surname>Akhmetova</surname> <given-names>L</given-names></name><name><surname>Ahkmetova</surname> <given-names>L</given-names></name><name><surname>Pauli</surname> <given-names>A</given-names></name><name><surname>Montague</surname> <given-names>TG</given-names></name><name><surname>Zimmerman</surname> <given-names>S</given-names></name><name><surname>Richter</surname> <given-names>C</given-names></name><name><surname>Schier</surname> <given-names>AF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Efficient mutagenesis by Cas9 protein-mediated oligonucleotide insertion and large-scale assessment of single-guide RNAs</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e98186</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0098186</pub-id><pub-id pub-id-type="pmid">24873830</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelb</surname> <given-names>BD</given-names></name><name><surname>Chung</surname> <given-names>WK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Complex genetics and the etiology of human congenital heart disease</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>4</volume><elocation-id>a013953</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a013953</pub-id><pub-id pub-id-type="pmid">24985128</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gessert</surname> <given-names>S</given-names></name><name><surname>Kühl</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The multiple phases and faces of wnt signaling during cardiac differentiation and development</article-title><source>Circulation Research</source><volume>107</volume><fpage>186</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.221531</pub-id><pub-id pub-id-type="pmid">20651295</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossfeld</surname> <given-names>P</given-names></name><name><surname>Nie</surname> <given-names>S</given-names></name><name><surname>Lin</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Anderson</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hypoplastic left heart syndrome: a new paradigm for an old disease?</article-title><source>Journal of Cardiovascular Development and Disease</source><volume>6</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.3390/jcdd6010010</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinton</surname> <given-names>RB</given-names></name><name><surname>Martin</surname> <given-names>LJ</given-names></name><name><surname>Tabangin</surname> <given-names>ME</given-names></name><name><surname>Mazwi</surname> <given-names>ML</given-names></name><name><surname>Cripe</surname> <given-names>LH</given-names></name><name><surname>Benson</surname> <given-names>DW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Hypoplastic left heart syndrome is heritable</article-title><source>Journal of the American College of Cardiology</source><volume>50</volume><fpage>1590</fpage><lpage>1595</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2007.07.021</pub-id><pub-id pub-id-type="pmid">17936159</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoshijima</surname> <given-names>K</given-names></name><name><surname>Jurynec</surname> <given-names>MJ</given-names></name><name><surname>Klatt Shaw</surname> <given-names>D</given-names></name><name><surname>Jacobi</surname> <given-names>AM</given-names></name><name><surname>Behlke</surname> <given-names>MA</given-names></name><name><surname>Grunwald</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Highly efficient CRISPR-Cas9-Based methods for generating deletion mutations and F0 embryos that lack gene function in zebrafish</article-title><source>Developmental Cell</source><volume>51</volume><fpage>645</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2019.10.004</pub-id><pub-id pub-id-type="pmid">31708433</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hrstka</surname> <given-names>SC</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Nelson</surname> <given-names>TJ</given-names></name><collab>Wanek Program Genetics Pipeline Group</collab></person-group><year iso-8601-date="2017">2017</year><article-title><italic>NOTCH1</italic>-Dependent nitric oxide signaling deficiency in hypoplastic left heart syndrome revealed through Patient-Specific phenotypes detected in bioengineered cardiogenesis</article-title><source>Stem Cells</source><volume>35</volume><fpage>1106</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1002/stem.2582</pub-id><pub-id pub-id-type="pmid">28142228</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Flockhart</surname> <given-names>I</given-names></name><name><surname>Vinayagam</surname> <given-names>A</given-names></name><name><surname>Bergwitz</surname> <given-names>C</given-names></name><name><surname>Berger</surname> <given-names>B</given-names></name><name><surname>Perrimon</surname> <given-names>N</given-names></name><name><surname>Mohr</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>An integrative approach to ortholog prediction for disease-focused and other functional studies</article-title><source>BMC Bioinformatics</source><volume>12</volume><elocation-id>357</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-12-357</pub-id><pub-id pub-id-type="pmid">21880147</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>CJ</given-names></name><name><surname>Tu</surname> <given-names>CT</given-names></name><name><surname>Hsiao</surname> <given-names>CD</given-names></name><name><surname>Hsieh</surname> <given-names>FJ</given-names></name><name><surname>Tsai</surname> <given-names>HJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Germ-line transmission of a myocardium-specific GFP transgene reveals critical regulatory elements in the cardiac myosin light chain 2 promoter of zebrafish</article-title><source>Developmental Dynamics</source><volume>228</volume><fpage>30</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1002/dvdy.10356</pub-id><pub-id pub-id-type="pmid">12950077</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iascone</surname> <given-names>M</given-names></name><name><surname>Ciccone</surname> <given-names>R</given-names></name><name><surname>Galletti</surname> <given-names>L</given-names></name><name><surname>Marchetti</surname> <given-names>D</given-names></name><name><surname>Seddio</surname> <given-names>F</given-names></name><name><surname>Lincesso</surname> <given-names>AR</given-names></name><name><surname>Pezzoli</surname> <given-names>L</given-names></name><name><surname>Vetro</surname> <given-names>A</given-names></name><name><surname>Barachetti</surname> <given-names>D</given-names></name><name><surname>Boni</surname> <given-names>L</given-names></name><name><surname>Federici</surname> <given-names>D</given-names></name><name><surname>Soto</surname> <given-names>AM</given-names></name><name><surname>Comas</surname> <given-names>JV</given-names></name><name><surname>Ferrazzi</surname> <given-names>P</given-names></name><name><surname>Zuffardi</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Identification of de novo mutations and rare variants in hypoplastic left heart syndrome</article-title><source>Clinical Genetics</source><volume>81</volume><fpage>542</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1111/j.1399-0004.2011.01674.x</pub-id><pub-id pub-id-type="pmid">21457232</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irion</surname> <given-names>U</given-names></name><name><surname>Krauss</surname> <given-names>J</given-names></name><name><surname>Nüsslein-Volhard</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Precise and efficient genome editing in zebrafish using the CRISPR/Cas9 system</article-title><source>Development</source><volume>141</volume><fpage>4827</fpage><lpage>4830</lpage><pub-id pub-id-type="doi">10.1242/dev.115584</pub-id><pub-id pub-id-type="pmid">25411213</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jun</surname> <given-names>G</given-names></name><name><surname>Flickinger</surname> <given-names>M</given-names></name><name><surname>Hetrick</surname> <given-names>KN</given-names></name><name><surname>Romm</surname> <given-names>JM</given-names></name><name><surname>Doheny</surname> <given-names>KF</given-names></name><name><surname>Abecasis</surname> <given-names>GR</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>Kang</surname> <given-names>HM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data</article-title><source>The American Journal of Human Genetics</source><volume>91</volume><fpage>839</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2012.09.004</pub-id><pub-id pub-id-type="pmid">23103226</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kantarci</surname> <given-names>S</given-names></name><name><surname>Ragge</surname> <given-names>NK</given-names></name><name><surname>Thomas</surname> <given-names>NS</given-names></name><name><surname>Robinson</surname> <given-names>DO</given-names></name><name><surname>Noonan</surname> <given-names>KM</given-names></name><name><surname>Russell</surname> <given-names>MK</given-names></name><name><surname>Donnai</surname> <given-names>D</given-names></name><name><surname>Raymond</surname> <given-names>FL</given-names></name><name><surname>Walsh</surname> <given-names>CA</given-names></name><name><surname>Donahoe</surname> <given-names>PK</given-names></name><name><surname>Pober</surname> <given-names>BR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Donnai-Barrow syndrome (DBS/FOAR) in a child with a homozygous <italic>LRP2</italic> mutation due to complete chromosome 2 paternal isodisomy</article-title><source>American Journal of Medical Genetics Part A</source><volume>146A</volume><fpage>1842</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.32381</pub-id><pub-id pub-id-type="pmid">18553518</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kathiriya</surname> <given-names>IS</given-names></name><name><surname>Nora</surname> <given-names>EP</given-names></name><name><surname>Bruneau</surname> <given-names>BG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Investigating the transcriptional control of cardiovascular development</article-title><source>Circulation Research</source><volume>116</volume><fpage>700</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.302832</pub-id><pub-id pub-id-type="pmid">25677518</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawagishi</surname> <given-names>H</given-names></name><name><surname>Xiong</surname> <given-names>J</given-names></name><name><surname>Rovira</surname> <given-names>II</given-names></name><name><surname>Pan</surname> <given-names>H</given-names></name><name><surname>Yan</surname> <given-names>Y</given-names></name><name><surname>Fleischmann</surname> <given-names>BK</given-names></name><name><surname>Yamada</surname> <given-names>M</given-names></name><name><surname>Finkel</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Sonic hedgehog signaling regulates the mammalian cardiac regenerative response</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>123</volume><fpage>180</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2018.09.005</pub-id><pub-id pub-id-type="pmid">30236923</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kircher</surname> <given-names>M</given-names></name><name><surname>Witten</surname> <given-names>DM</given-names></name><name><surname>Jain</surname> <given-names>P</given-names></name><name><surname>O'Roak</surname> <given-names>BJ</given-names></name><name><surname>Cooper</surname> <given-names>GM</given-names></name><name><surname>Shendure</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A general framework for estimating the relative pathogenicity of human genetic variants</article-title><source>Nature Genetics</source><volume>46</volume><fpage>310</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1038/ng.2892</pub-id><pub-id pub-id-type="pmid">24487276</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname> <given-names>J</given-names></name><name><surname>Yoshida</surname> <given-names>M</given-names></name><name><surname>Tarui</surname> <given-names>S</given-names></name><name><surname>Hirata</surname> <given-names>M</given-names></name><name><surname>Nagai</surname> <given-names>Y</given-names></name><name><surname>Kasahara</surname> <given-names>S</given-names></name><name><surname>Naruse</surname> <given-names>K</given-names></name><name><surname>Ito</surname> <given-names>H</given-names></name><name><surname>Sano</surname> <given-names>S</given-names></name><name><surname>Oh</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Directed differentiation of patient-specific induced pluripotent stem cells identifies the transcriptional repression and epigenetic modification of NKX2-5, HAND1, and NOTCH1 in hypoplastic left heart syndrome</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e102796</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0102796</pub-id><pub-id pub-id-type="pmid">25050861</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Wu</surname> <given-names>MC</given-names></name><name><surname>Lin</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Optimal tests for rare variant effects in sequencing association studies</article-title><source>Biostatistics</source><volume>13</volume><fpage>762</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1093/biostatistics/kxs014</pub-id><pub-id pub-id-type="pmid">22699862</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lek</surname> <given-names>M</given-names></name><name><surname>Karczewski</surname> <given-names>KJ</given-names></name><name><surname>Minikel</surname> <given-names>EV</given-names></name><name><surname>Samocha</surname> <given-names>KE</given-names></name><name><surname>Banks</surname> <given-names>E</given-names></name><name><surname>Fennell</surname> <given-names>T</given-names></name><name><surname>O'Donnell-Luria</surname> <given-names>AH</given-names></name><name><surname>Ware</surname> <given-names>JS</given-names></name><name><surname>Hill</surname> <given-names>AJ</given-names></name><name><surname>Cummings</surname> <given-names>BB</given-names></name><name><surname>Tukiainen</surname> <given-names>T</given-names></name><name><surname>Birnbaum</surname> <given-names>DP</given-names></name><name><surname>Kosmicki</surname> <given-names>JA</given-names></name><name><surname>Duncan</surname> <given-names>LE</given-names></name><name><surname>Estrada</surname> <given-names>K</given-names></name><name><surname>Zhao</surname> <given-names>F</given-names></name><name><surname>Zou</surname> <given-names>J</given-names></name><name><surname>Pierce-Hoffman</surname> <given-names>E</given-names></name><name><surname>Berghout</surname> <given-names>J</given-names></name><name><surname>Cooper</surname> <given-names>DN</given-names></name><name><surname>Deflaux</surname> <given-names>N</given-names></name><name><surname>DePristo</surname> <given-names>M</given-names></name><name><surname>Do</surname> <given-names>R</given-names></name><name><surname>Flannick</surname> <given-names>J</given-names></name><name><surname>Fromer</surname> <given-names>M</given-names></name><name><surname>Gauthier</surname> <given-names>L</given-names></name><name><surname>Goldstein</surname> <given-names>J</given-names></name><name><surname>Gupta</surname> <given-names>N</given-names></name><name><surname>Howrigan</surname> <given-names>D</given-names></name><name><surname>Kiezun</surname> <given-names>A</given-names></name><name><surname>Kurki</surname> <given-names>MI</given-names></name><name><surname>Moonshine</surname> <given-names>AL</given-names></name><name><surname>Natarajan</surname> <given-names>P</given-names></name><name><surname>Orozco</surname> <given-names>L</given-names></name><name><surname>Peloso</surname> <given-names>GM</given-names></name><name><surname>Poplin</surname> <given-names>R</given-names></name><name><surname>Rivas</surname> <given-names>MA</given-names></name><name><surname>Ruano-Rubio</surname> <given-names>V</given-names></name><name><surname>Rose</surname> <given-names>SA</given-names></name><name><surname>Ruderfer</surname> <given-names>DM</given-names></name><name><surname>Shakir</surname> <given-names>K</given-names></name><name><surname>Stenson</surname> <given-names>PD</given-names></name><name><surname>Stevens</surname> <given-names>C</given-names></name><name><surname>Thomas</surname> <given-names>BP</given-names></name><name><surname>Tiao</surname> <given-names>G</given-names></name><name><surname>Tusie-Luna</surname> <given-names>MT</given-names></name><name><surname>Weisburd</surname> <given-names>B</given-names></name><name><surname>Won</surname> <given-names>HH</given-names></name><name><surname>Yu</surname> <given-names>D</given-names></name><name><surname>Altshuler</surname> <given-names>DM</given-names></name><name><surname>Ardissino</surname> <given-names>D</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>Danesh</surname> <given-names>J</given-names></name><name><surname>Donnelly</surname> <given-names>S</given-names></name><name><surname>Elosua</surname> <given-names>R</given-names></name><name><surname>Florez</surname> <given-names>JC</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Glatt</surname> <given-names>SJ</given-names></name><name><surname>Hultman</surname> <given-names>CM</given-names></name><name><surname>Kathiresan</surname> <given-names>S</given-names></name><name><surname>Laakso</surname> <given-names>M</given-names></name><name><surname>McCarroll</surname> <given-names>S</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>McGovern</surname> <given-names>D</given-names></name><name><surname>McPherson</surname> <given-names>R</given-names></name><name><surname>Neale</surname> <given-names>BM</given-names></name><name><surname>Palotie</surname> <given-names>A</given-names></name><name><surname>Purcell</surname> <given-names>SM</given-names></name><name><surname>Saleheen</surname> <given-names>D</given-names></name><name><surname>Scharf</surname> <given-names>JM</given-names></name><name><surname>Sklar</surname> <given-names>P</given-names></name><name><surname>Sullivan</surname> <given-names>PF</given-names></name><name><surname>Tuomilehto</surname> <given-names>J</given-names></name><name><surname>Tsuang</surname> <given-names>MT</given-names></name><name><surname>Watkins</surname> <given-names>HC</given-names></name><name><surname>Wilson</surname> <given-names>JG</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>MacArthur</surname> <given-names>DG</given-names></name><collab>Exome Aggregation Consortium</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title><source>Nature</source><volume>536</volume><fpage>285</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1038/nature19057</pub-id><pub-id pub-id-type="pmid">27535533</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lian</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Azarin</surname> <given-names>SM</given-names></name><name><surname>Zhu</surname> <given-names>K</given-names></name><name><surname>Hazeltine</surname> <given-names>LB</given-names></name><name><surname>Bao</surname> <given-names>X</given-names></name><name><surname>Hsiao</surname> <given-names>C</given-names></name><name><surname>Kamp</surname> <given-names>TJ</given-names></name><name><surname>Palecek</surname> <given-names>SP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating wnt/β-catenin signaling under fully defined conditions</article-title><source>Nature Protocols</source><volume>8</volume><fpage>162</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1038/nprot.2012.150</pub-id><pub-id pub-id-type="pmid">23257984</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Yagi</surname> <given-names>H</given-names></name><name><surname>Saeed</surname> <given-names>S</given-names></name><name><surname>Bais</surname> <given-names>AS</given-names></name><name><surname>Gabriel</surname> <given-names>GC</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Peterson</surname> <given-names>KA</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Schwartz</surname> <given-names>MC</given-names></name><name><surname>Reynolds</surname> <given-names>WT</given-names></name><name><surname>Saydmohammed</surname> <given-names>M</given-names></name><name><surname>Gibbs</surname> <given-names>B</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Devine</surname> <given-names>W</given-names></name><name><surname>Chatterjee</surname> <given-names>B</given-names></name><name><surname>Klena</surname> <given-names>NT</given-names></name><name><surname>Kostka</surname> <given-names>D</given-names></name><name><surname>de Mesy Bentley</surname> <given-names>KL</given-names></name><name><surname>Ganapathiraju</surname> <given-names>MK</given-names></name><name><surname>Dexheimer</surname> <given-names>P</given-names></name><name><surname>Leatherbury</surname> <given-names>L</given-names></name><name><surname>Khalifa</surname> <given-names>O</given-names></name><name><surname>Bhagat</surname> <given-names>A</given-names></name><name><surname>Zahid</surname> <given-names>M</given-names></name><name><surname>Pu</surname> <given-names>W</given-names></name><name><surname>Watkins</surname> <given-names>S</given-names></name><name><surname>Grossfeld</surname> <given-names>P</given-names></name><name><surname>Murray</surname> <given-names>SA</given-names></name><name><surname>Porter</surname> <given-names>GA</given-names></name><name><surname>Tsang</surname> <given-names>M</given-names></name><name><surname>Martin</surname> <given-names>LJ</given-names></name><name><surname>Benson</surname> <given-names>DW</given-names></name><name><surname>Aronow</surname> <given-names>BJ</given-names></name><name><surname>Lo</surname> <given-names>CW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The complex genetics of hypoplastic left heart syndrome</article-title><source>Nature Genetics</source><volume>49</volume><fpage>1152</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1038/ng.3870</pub-id><pub-id pub-id-type="pmid">28530678</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Fernandez</surname> <given-names>A</given-names></name><name><surname>Nelson</surname> <given-names>TJ</given-names></name><name><surname>Ikeda</surname> <given-names>Y</given-names></name><name><surname>Terzic</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>c-MYC independent nuclear reprogramming favors cardiogenic potential of induced pluripotent stem cells</article-title><source>Journal of Cardiovascular Translational Research</source><volume>3</volume><fpage>13</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s12265-009-9150-5</pub-id><pub-id pub-id-type="pmid">20221419</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsa</surname> <given-names>E</given-names></name><name><surname>Ahrens</surname> <given-names>JH</given-names></name><name><surname>Wu</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Human induced pluripotent stem cells as a platform for personalized and precision cardiovascular medicine</article-title><source>Physiological Reviews</source><volume>96</volume><fpage>1093</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1152/physrev.00036.2015</pub-id><pub-id pub-id-type="pmid">27335446</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname> <given-names>KL</given-names></name><name><surname>Marengo</surname> <given-names>L</given-names></name><name><surname>Canfield</surname> <given-names>M</given-names></name><name><surname>Langlois</surname> <given-names>P</given-names></name><name><surname>Fixler</surname> <given-names>D</given-names></name><name><surname>Belmont</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Epidemiology of noncomplex left ventricular outflow tract obstruction malformations (aortic valve Stenosis, coarctation of the aorta, hypoplastic left heart syndrome) in Texas, 1999-2001</article-title><source>Birth Defects Research Part A: Clinical and Molecular Teratology</source><volume>73</volume><fpage>555</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1002/bdra.20169</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname> <given-names>A</given-names></name><name><surname>Hanna</surname> <given-names>M</given-names></name><name><surname>Banks</surname> <given-names>E</given-names></name><name><surname>Sivachenko</surname> <given-names>A</given-names></name><name><surname>Cibulskis</surname> <given-names>K</given-names></name><name><surname>Kernytsky</surname> <given-names>A</given-names></name><name><surname>Garimella</surname> <given-names>K</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name><name><surname>Gabriel</surname> <given-names>S</given-names></name><name><surname>Daly</surname> <given-names>M</given-names></name><name><surname>DePristo</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</article-title><source>Genome Research</source><volume>20</volume><fpage>1297</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1101/gr.107524.110</pub-id><pub-id pub-id-type="pmid">20644199</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercola</surname> <given-names>M</given-names></name><name><surname>Colas</surname> <given-names>A</given-names></name><name><surname>Willems</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Induced pluripotent stem cells in cardiovascular drug discovery</article-title><source>Circulation Research</source><volume>112</volume><fpage>534</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.250266</pub-id><pub-id pub-id-type="pmid">23371902</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moretti</surname> <given-names>A</given-names></name><name><surname>Laugwitz</surname> <given-names>KL</given-names></name><name><surname>Dorn</surname> <given-names>T</given-names></name><name><surname>Sinnecker</surname> <given-names>D</given-names></name><name><surname>Mummery</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Pluripotent stem cell models of human heart disease</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>3</volume><elocation-id>a014027</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a014027</pub-id><pub-id pub-id-type="pmid">24186488</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Münz</surname> <given-names>M</given-names></name><name><surname>Ruark</surname> <given-names>E</given-names></name><name><surname>Renwick</surname> <given-names>A</given-names></name><name><surname>Ramsay</surname> <given-names>E</given-names></name><name><surname>Clarke</surname> <given-names>M</given-names></name><name><surname>Mahamdallie</surname> <given-names>S</given-names></name><name><surname>Cloke</surname> <given-names>V</given-names></name><name><surname>Seal</surname> <given-names>S</given-names></name><name><surname>Strydom</surname> <given-names>A</given-names></name><name><surname>Lunter</surname> <given-names>G</given-names></name><name><surname>Rahman</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CSN and CAVA: variant annotation tools for rapid, robust next-generation sequencing analysis in the clinical setting</article-title><source>Genome Medicine</source><volume>7</volume><elocation-id>76</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-015-0195-6</pub-id><pub-id pub-id-type="pmid">26315209</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayanan</surname> <given-names>AK</given-names></name><name><surname>Hitz</surname> <given-names>BC</given-names></name><name><surname>Davis</surname> <given-names>CA</given-names></name><name><surname>Sloan</surname> <given-names>CA</given-names></name><name><surname>Chan</surname> <given-names>ET</given-names></name><name><surname>Tanaka</surname> <given-names>FY</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The encyclopedia of DNA elements (ENCODE): data portal update</article-title><source>Nucleic Acids Research</source><volume>46</volume><elocation-id>gkx1081</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkx1081</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ocorr</surname> <given-names>K</given-names></name><name><surname>Reeves</surname> <given-names>NL</given-names></name><name><surname>Wessells</surname> <given-names>RJ</given-names></name><name><surname>Fink</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>HS</given-names></name><name><surname>Akasaka</surname> <given-names>T</given-names></name><name><surname>Yasuda</surname> <given-names>S</given-names></name><name><surname>Metzger</surname> <given-names>JM</given-names></name><name><surname>Giles</surname> <given-names>W</given-names></name><name><surname>Posakony</surname> <given-names>JW</given-names></name><name><surname>Bodmer</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>KCNQ potassium channel mutations cause cardiac arrhythmias in <italic>Drosophila</italic> that mimic the effects of aging</article-title><source>PNAS</source><volume>104</volume><fpage>3943</fpage><lpage>3948</lpage><pub-id pub-id-type="doi">10.1073/pnas.0609278104</pub-id><pub-id pub-id-type="pmid">17360457</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ocorr</surname> <given-names>K</given-names></name><name><surname>Fink</surname> <given-names>M</given-names></name><name><surname>Cammarato</surname> <given-names>A</given-names></name><name><surname>Bernstein</surname> <given-names>S</given-names></name><name><surname>Bodmer</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Semi-automated optical heartbeat analysis of small hearts</article-title><source>Journal of Visualized Experiments</source><volume>31</volume><elocation-id>1435</elocation-id><pub-id pub-id-type="doi">10.3791/1435</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ocorr</surname> <given-names>K</given-names></name><name><surname>Vogler</surname> <given-names>G</given-names></name><name><surname>Bodmer</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Methods to assess <italic>Drosophila</italic> heart development, function and aging</article-title><source>Methods</source><volume>68</volume><fpage>265</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2014.03.031</pub-id><pub-id pub-id-type="pmid">24727147</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname> <given-names>JE</given-names></name><name><surname>Ryu</surname> <given-names>E</given-names></name><name><surname>Johnson</surname> <given-names>KJ</given-names></name><name><surname>Koenig</surname> <given-names>BA</given-names></name><name><surname>Maschke</surname> <given-names>KJ</given-names></name><name><surname>Morrisette</surname> <given-names>JA</given-names></name><name><surname>Liebow</surname> <given-names>M</given-names></name><name><surname>Takahashi</surname> <given-names>PY</given-names></name><name><surname>Fredericksen</surname> <given-names>ZS</given-names></name><name><surname>Sharma</surname> <given-names>RG</given-names></name><name><surname>Anderson</surname> <given-names>KS</given-names></name><name><surname>Hathcock</surname> <given-names>MA</given-names></name><name><surname>Carnahan</surname> <given-names>JA</given-names></name><name><surname>Pathak</surname> <given-names>J</given-names></name><name><surname>Lindor</surname> <given-names>NM</given-names></name><name><surname>Beebe</surname> <given-names>TJ</given-names></name><name><surname>Thibodeau</surname> <given-names>SN</given-names></name><name><surname>Cerhan</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The mayo clinic biobank: a building block for individualized medicine</article-title><source>Mayo Clinic Proceedings</source><volume>88</volume><fpage>952</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2013.06.006</pub-id><pub-id pub-id-type="pmid">24001487</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierpont</surname> <given-names>ME</given-names></name><name><surname>Brueckner</surname> <given-names>M</given-names></name><name><surname>Chung</surname> <given-names>WK</given-names></name><name><surname>Garg</surname> <given-names>V</given-names></name><name><surname>Lacro</surname> <given-names>RV</given-names></name><name><surname>McGuire</surname> <given-names>AL</given-names></name><name><surname>Mital</surname> <given-names>S</given-names></name><name><surname>Priest</surname> <given-names>JR</given-names></name><name><surname>Pu</surname> <given-names>WT</given-names></name><name><surname>Roberts</surname> <given-names>A</given-names></name><name><surname>Ware</surname> <given-names>SM</given-names></name><name><surname>Gelb</surname> <given-names>BD</given-names></name><name><surname>Russell</surname> <given-names>MW</given-names></name><collab>American Heart Association Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Genomic and Precision Medicine</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Genetic basis for congenital heart disease: revisited: a scientific statement from the american heart association</article-title><source>Circulation</source><volume>138</volume><fpage>e653</fpage><lpage>e711</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000606</pub-id><pub-id pub-id-type="pmid">30571578</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pradhan</surname> <given-names>A</given-names></name><name><surname>Zeng</surname> <given-names>XI</given-names></name><name><surname>Sidhwani</surname> <given-names>P</given-names></name><name><surname>Marques</surname> <given-names>SR</given-names></name><name><surname>George</surname> <given-names>V</given-names></name><name><surname>Targoff</surname> <given-names>KL</given-names></name><name><surname>Chi</surname> <given-names>NC</given-names></name><name><surname>Yelon</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>FGF signaling enforces cardiac chamber identity in the developing ventricle</article-title><source>Development</source><volume>144</volume><fpage>1328</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1242/dev.143719</pub-id><pub-id pub-id-type="pmid">28232600</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname> <given-names>L</given-names></name><name><surname>Wythe</surname> <given-names>JD</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Cartry</surname> <given-names>J</given-names></name><name><surname>Vogler</surname> <given-names>G</given-names></name><name><surname>Mohapatra</surname> <given-names>B</given-names></name><name><surname>Otway</surname> <given-names>RT</given-names></name><name><surname>Huang</surname> <given-names>Y</given-names></name><name><surname>King</surname> <given-names>IN</given-names></name><name><surname>Maillet</surname> <given-names>M</given-names></name><name><surname>Zheng</surname> <given-names>Y</given-names></name><name><surname>Crawley</surname> <given-names>T</given-names></name><name><surname>Taghli-Lamallem</surname> <given-names>O</given-names></name><name><surname>Semsarian</surname> <given-names>C</given-names></name><name><surname>Dunwoodie</surname> <given-names>S</given-names></name><name><surname>Winlaw</surname> <given-names>D</given-names></name><name><surname>Harvey</surname> <given-names>RP</given-names></name><name><surname>Fatkin</surname> <given-names>D</given-names></name><name><surname>Towbin</surname> <given-names>JA</given-names></name><name><surname>Molkentin</surname> <given-names>JD</given-names></name><name><surname>Srivastava</surname> <given-names>D</given-names></name><name><surname>Ocorr</surname> <given-names>K</given-names></name><name><surname>Bruneau</surname> <given-names>BG</given-names></name><name><surname>Bodmer</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Tinman/Nkx2-5 acts via miR-1 and upstream of Cdc42 to regulate heart function across species</article-title><source>The Journal of Cell Biology</source><volume>193</volume><fpage>1181</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1083/jcb.201006114</pub-id><pub-id pub-id-type="pmid">21690310</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname> <given-names>L</given-names></name><name><surname>Srivastava</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Direct cardiac reprogramming: from developmental biology to cardiac regeneration</article-title><source>Circulation Research</source><volume>113</volume><elocation-id>300625</elocation-id><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.112.300625</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raney</surname> <given-names>BJ</given-names></name><name><surname>Dreszer</surname> <given-names>TR</given-names></name><name><surname>Barber</surname> <given-names>GP</given-names></name><name><surname>Clawson</surname> <given-names>H</given-names></name><name><surname>Fujita</surname> <given-names>PA</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Nguyen</surname> <given-names>N</given-names></name><name><surname>Paten</surname> <given-names>B</given-names></name><name><surname>Zweig</surname> <given-names>AS</given-names></name><name><surname>Karolchik</surname> <given-names>D</given-names></name><name><surname>Kent</surname> <given-names>WJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Track data hubs enable visualization of user-defined genome-wide annotations on the UCSC genome browser</article-title><source>Bioinformatics</source><volume>30</volume><fpage>1003</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt637</pub-id><pub-id pub-id-type="pmid">24227676</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saraf</surname> <given-names>A</given-names></name><name><surname>Book</surname> <given-names>WM</given-names></name><name><surname>Nelson</surname> <given-names>TJ</given-names></name><name><surname>Xu</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hypoplastic left heart syndrome: from bedside to bench and back</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>135</volume><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2019.08.005</pub-id><pub-id pub-id-type="pmid">31419439</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasse</surname> <given-names>P</given-names></name><name><surname>Malan</surname> <given-names>D</given-names></name><name><surname>Fleischmann</surname> <given-names>M</given-names></name><name><surname>Roell</surname> <given-names>W</given-names></name><name><surname>Gustafsson</surname> <given-names>E</given-names></name><name><surname>Bostani</surname> <given-names>T</given-names></name><name><surname>Fan</surname> <given-names>Y</given-names></name><name><surname>Kolbe</surname> <given-names>T</given-names></name><name><surname>Breitbach</surname> <given-names>M</given-names></name><name><surname>Addicks</surname> <given-names>K</given-names></name><name><surname>Welz</surname> <given-names>A</given-names></name><name><surname>Brem</surname> <given-names>G</given-names></name><name><surname>Hescheler</surname> <given-names>J</given-names></name><name><surname>Aszodi</surname> <given-names>A</given-names></name><name><surname>Costell</surname> <given-names>M</given-names></name><name><surname>Bloch</surname> <given-names>W</given-names></name><name><surname>Fleischmann</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Perlecan is critical for heart stability</article-title><source>Cardiovascular Research</source><volume>80</volume><fpage>435</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvn225</pub-id><pub-id pub-id-type="pmid">18694874</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroeder</surname> <given-names>AM</given-names></name><name><surname>Allahyari</surname> <given-names>M</given-names></name><name><surname>Vogler</surname> <given-names>G</given-names></name><name><surname>Missinato</surname> <given-names>MA</given-names></name><name><surname>Nielsen</surname> <given-names>T</given-names></name><name><surname>Yu</surname> <given-names>MS</given-names></name><name><surname>Theis</surname> <given-names>JL</given-names></name><name><surname>Larsen</surname> <given-names>LA</given-names></name><name><surname>Goyal</surname> <given-names>P</given-names></name><name><surname>Rosenfeld</surname> <given-names>JA</given-names></name><name><surname>Nelson</surname> <given-names>TJ</given-names></name><name><surname>Olson</surname> <given-names>TM</given-names></name><name><surname>Colas</surname> <given-names>AR</given-names></name><name><surname>Grossfeld</surname> <given-names>P</given-names></name><name><surname>Bodmer</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Model system identification of novel congenital heart disease gene candidates: focus on RPL13</article-title><source>Human Molecular Genetics</source><volume>28</volume><fpage>3954</fpage><lpage>3969</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddz213</pub-id><pub-id pub-id-type="pmid">31625562</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schumacher</surname> <given-names>JA</given-names></name><name><surname>Bloomekatz</surname> <given-names>J</given-names></name><name><surname>Garavito-Aguilar</surname> <given-names>ZV</given-names></name><name><surname>Yelon</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>tal1 regulates the formation of intercellular junctions and the maintenance of identity in the endocardium</article-title><source>Developmental Biology</source><volume>383</volume><fpage>214</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2013.09.019</pub-id><pub-id pub-id-type="pmid">24075907</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Şentürk</surname> <given-names>M</given-names></name><name><surname>Bellen</surname> <given-names>HJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Genetic strategies to tackle neurological diseases in fruit flies</article-title><source>Current Opinion in Neurobiology</source><volume>50</volume><fpage>24</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2017.10.017</pub-id><pub-id pub-id-type="pmid">29128849</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stähli</surname> <given-names>BE</given-names></name><name><surname>Gebhard</surname> <given-names>C</given-names></name><name><surname>Biaggi</surname> <given-names>P</given-names></name><name><surname>Klaassen</surname> <given-names>S</given-names></name><name><surname>Valsangiacomo Buechel</surname> <given-names>E</given-names></name><name><surname>Attenhofer Jost</surname> <given-names>CH</given-names></name><name><surname>Jenni</surname> <given-names>R</given-names></name><name><surname>Tanner</surname> <given-names>FC</given-names></name><name><surname>Greutmann</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Left ventricular non-compaction: prevalence in congenital heart disease</article-title><source>International Journal of Cardiology</source><volume>167</volume><fpage>2477</fpage><lpage>2481</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2012.05.095</pub-id><pub-id pub-id-type="pmid">22704867</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname> <given-names>K</given-names></name><name><surname>Yamanaka</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors</article-title><source>Cell</source><volume>126</volume><fpage>663</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.07.024</pub-id><pub-id pub-id-type="pmid">16904174</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talbot</surname> <given-names>JC</given-names></name><name><surname>Amacher</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A streamlined CRISPR pipeline to reliably generate zebrafish frameshifting alleles</article-title><source>Zebrafish</source><volume>11</volume><fpage>583</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1089/zeb.2014.1047</pub-id><pub-id pub-id-type="pmid">25470533</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theis</surname> <given-names>JL</given-names></name><name><surname>Hrstka</surname> <given-names>SC</given-names></name><name><surname>Evans</surname> <given-names>JM</given-names></name><name><surname>O'Byrne</surname> <given-names>MM</given-names></name><name><surname>de Andrade</surname> <given-names>M</given-names></name><name><surname>O'Leary</surname> <given-names>PW</given-names></name><name><surname>Nelson</surname> <given-names>TJ</given-names></name><name><surname>Olson</surname> <given-names>TM</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>Compound heterozygous NOTCH1 mutations underlie impaired cardiogenesis in a patient with hypoplastic left heart syndrome</article-title><source>Human Genetics</source><volume>134</volume><fpage>1003</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1007/s00439-015-1582-1</pub-id><pub-id pub-id-type="pmid">26164125</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theis</surname> <given-names>JL</given-names></name><name><surname>Zimmermann</surname> <given-names>MT</given-names></name><name><surname>Evans</surname> <given-names>JM</given-names></name><name><surname>Eckloff</surname> <given-names>BW</given-names></name><name><surname>Wieben</surname> <given-names>ED</given-names></name><name><surname>Qureshi</surname> <given-names>MY</given-names></name><name><surname>O'Leary</surname> <given-names>PW</given-names></name><name><surname>Olson</surname> <given-names>TM</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>Recessive MYH6 mutations in hypoplastic left heart with reduced ejection fraction</article-title><source>Circulation. Cardiovascular Genetics</source><volume>8</volume><fpage>564</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1161/CIRCGENETICS.115.001070</pub-id><pub-id pub-id-type="pmid">26085007</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname> <given-names>A-S</given-names></name><name><surname>Engel</surname> <given-names>FB</given-names></name><name><surname>Keating</surname> <given-names>MT</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes</article-title><source>Chemistry &amp; Biology</source><volume>13</volume><fpage>957</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2006.08.004</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Auwera</surname> <given-names>GA</given-names></name><name><surname>Carneiro</surname> <given-names>MO</given-names></name><name><surname>Hartl</surname> <given-names>C</given-names></name><name><surname>Poplin</surname> <given-names>R</given-names></name><name><surname>Del Angel</surname> <given-names>G</given-names></name><name><surname>Levy-Moonshine</surname> <given-names>A</given-names></name><name><surname>Jordan</surname> <given-names>T</given-names></name><name><surname>Shakir</surname> <given-names>K</given-names></name><name><surname>Roazen</surname> <given-names>D</given-names></name><name><surname>Thibault</surname> <given-names>J</given-names></name><name><surname>Banks</surname> <given-names>E</given-names></name><name><surname>Garimella</surname> <given-names>KV</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name><name><surname>Gabriel</surname> <given-names>S</given-names></name><name><surname>DePristo</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>From FastQ data to high-confidence variant calls: the genome AnalysisTtoolkit best practices pipeline</article-title><source>Current Protocols in Bioinformatics</source><volume>43</volume><elocation-id>bi1110s43</elocation-id><pub-id pub-id-type="doi">10.1002/0471250953.bi1110s43</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Harst</surname> <given-names>P</given-names></name><name><surname>van Setten</surname> <given-names>J</given-names></name><name><surname>Verweij</surname> <given-names>N</given-names></name><name><surname>Vogler</surname> <given-names>G</given-names></name><name><surname>Franke</surname> <given-names>L</given-names></name><name><surname>Maurano</surname> <given-names>MT</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Mateo Leach</surname> <given-names>I</given-names></name><name><surname>Eijgelsheim</surname> <given-names>M</given-names></name><name><surname>Sotoodehnia</surname> <given-names>N</given-names></name><name><surname>Hayward</surname> <given-names>C</given-names></name><name><surname>Sorice</surname> <given-names>R</given-names></name><name><surname>Meirelles</surname> <given-names>O</given-names></name><name><surname>Lyytikäinen</surname> <given-names>LP</given-names></name><name><surname>Polašek</surname> <given-names>O</given-names></name><name><surname>Tanaka</surname> <given-names>T</given-names></name><name><surname>Arking</surname> <given-names>DE</given-names></name><name><surname>Ulivi</surname> <given-names>S</given-names></name><name><surname>Trompet</surname> <given-names>S</given-names></name><name><surname>Müller-Nurasyid</surname> <given-names>M</given-names></name><name><surname>Smith</surname> <given-names>AV</given-names></name><name><surname>Dörr</surname> <given-names>M</given-names></name><name><surname>Kerr</surname> <given-names>KF</given-names></name><name><surname>Magnani</surname> <given-names>JW</given-names></name><name><surname>Del Greco M</surname> <given-names>F</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Nolte</surname> <given-names>IM</given-names></name><name><surname>Silva</surname> <given-names>CT</given-names></name><name><surname>Padmanabhan</surname> <given-names>S</given-names></name><name><surname>Tragante</surname> <given-names>V</given-names></name><name><surname>Esko</surname> <given-names>T</given-names></name><name><surname>Abecasis</surname> <given-names>GR</given-names></name><name><surname>Adriaens</surname> <given-names>ME</given-names></name><name><surname>Andersen</surname> <given-names>K</given-names></name><name><surname>Barnett</surname> <given-names>P</given-names></name><name><surname>Bis</surname> <given-names>JC</given-names></name><name><surname>Bodmer</surname> <given-names>R</given-names></name><name><surname>Buckley</surname> <given-names>BM</given-names></name><name><surname>Campbell</surname> <given-names>H</given-names></name><name><surname>Cannon</surname> <given-names>MV</given-names></name><name><surname>Chakravarti</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>LY</given-names></name><name><surname>Delitala</surname> <given-names>A</given-names></name><name><surname>Devereux</surname> <given-names>RB</given-names></name><name><surname>Doevendans</surname> <given-names>PA</given-names></name><name><surname>Dominiczak</surname> <given-names>AF</given-names></name><name><surname>Ferrucci</surname> <given-names>L</given-names></name><name><surname>Ford</surname> <given-names>I</given-names></name><name><surname>Gieger</surname> <given-names>C</given-names></name><name><surname>Harris</surname> <given-names>TB</given-names></name><name><surname>Haugen</surname> <given-names>E</given-names></name><name><surname>Heinig</surname> <given-names>M</given-names></name><name><surname>Hernandez</surname> <given-names>DG</given-names></name><name><surname>Hillege</surname> <given-names>HL</given-names></name><name><surname>Hirschhorn</surname> <given-names>JN</given-names></name><name><surname>Hofman</surname> <given-names>A</given-names></name><name><surname>Hubner</surname> <given-names>N</given-names></name><name><surname>Hwang</surname> <given-names>SJ</given-names></name><name><surname>Iorio</surname> <given-names>A</given-names></name><name><surname>Kähönen</surname> <given-names>M</given-names></name><name><surname>Kellis</surname> <given-names>M</given-names></name><name><surname>Kolcic</surname> <given-names>I</given-names></name><name><surname>Kooner</surname> <given-names>IK</given-names></name><name><surname>Kooner</surname> <given-names>JS</given-names></name><name><surname>Kors</surname> <given-names>JA</given-names></name><name><surname>Lakatta</surname> <given-names>EG</given-names></name><name><surname>Lage</surname> <given-names>K</given-names></name><name><surname>Launer</surname> <given-names>LJ</given-names></name><name><surname>Levy</surname> <given-names>D</given-names></name><name><surname>Lundby</surname> <given-names>A</given-names></name><name><surname>Macfarlane</surname> <given-names>PW</given-names></name><name><surname>May</surname> <given-names>D</given-names></name><name><surname>Meitinger</surname> <given-names>T</given-names></name><name><surname>Metspalu</surname> <given-names>A</given-names></name><name><surname>Nappo</surname> <given-names>S</given-names></name><name><surname>Naitza</surname> <given-names>S</given-names></name><name><surname>Neph</surname> <given-names>S</given-names></name><name><surname>Nord</surname> <given-names>AS</given-names></name><name><surname>Nutile</surname> <given-names>T</given-names></name><name><surname>Okin</surname> <given-names>PM</given-names></name><name><surname>Olsen</surname> <given-names>JV</given-names></name><name><surname>Oostra</surname> <given-names>BA</given-names></name><name><surname>Penninger</surname> <given-names>JM</given-names></name><name><surname>Pennacchio</surname> <given-names>LA</given-names></name><name><surname>Pers</surname> <given-names>TH</given-names></name><name><surname>Perz</surname> <given-names>S</given-names></name><name><surname>Peters</surname> <given-names>A</given-names></name><name><surname>Pinto</surname> <given-names>YM</given-names></name><name><surname>Pfeufer</surname> <given-names>A</given-names></name><name><surname>Pilia</surname> <given-names>MG</given-names></name><name><surname>Pramstaller</surname> <given-names>PP</given-names></name><name><surname>Prins</surname> <given-names>BP</given-names></name><name><surname>Raitakari</surname> <given-names>OT</given-names></name><name><surname>Raychaudhuri</surname> <given-names>S</given-names></name><name><surname>Rice</surname> <given-names>KM</given-names></name><name><surname>Rossin</surname> <given-names>EJ</given-names></name><name><surname>Rotter</surname> <given-names>JI</given-names></name><name><surname>Schafer</surname> <given-names>S</given-names></name><name><surname>Schlessinger</surname> <given-names>D</given-names></name><name><surname>Schmidt</surname> <given-names>CO</given-names></name><name><surname>Sehmi</surname> <given-names>J</given-names></name><name><surname>Silljé</surname> <given-names>HHW</given-names></name><name><surname>Sinagra</surname> <given-names>G</given-names></name><name><surname>Sinner</surname> <given-names>MF</given-names></name><name><surname>Slowikowski</surname> <given-names>K</given-names></name><name><surname>Soliman</surname> <given-names>EZ</given-names></name><name><surname>Spector</surname> <given-names>TD</given-names></name><name><surname>Spiering</surname> <given-names>W</given-names></name><name><surname>Stamatoyannopoulos</surname> <given-names>JA</given-names></name><name><surname>Stolk</surname> <given-names>RP</given-names></name><name><surname>Strauch</surname> <given-names>K</given-names></name><name><surname>Tan</surname> <given-names>ST</given-names></name><name><surname>Tarasov</surname> <given-names>KV</given-names></name><name><surname>Trinh</surname> <given-names>B</given-names></name><name><surname>Uitterlinden</surname> <given-names>AG</given-names></name><name><surname>van den Boogaard</surname> <given-names>M</given-names></name><name><surname>van Duijn</surname> <given-names>CM</given-names></name><name><surname>van Gilst</surname> <given-names>WH</given-names></name><name><surname>Viikari</surname> <given-names>JS</given-names></name><name><surname>Visscher</surname> <given-names>PM</given-names></name><name><surname>Vitart</surname> <given-names>V</given-names></name><name><surname>Völker</surname> <given-names>U</given-names></name><name><surname>Waldenberger</surname> <given-names>M</given-names></name><name><surname>Weichenberger</surname> <given-names>CX</given-names></name><name><surname>Westra</surname> <given-names>HJ</given-names></name><name><surname>Wijmenga</surname> <given-names>C</given-names></name><name><surname>Wolffenbuttel</surname> <given-names>BH</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Bezzina</surname> <given-names>CR</given-names></name><name><surname>Munroe</surname> <given-names>PB</given-names></name><name><surname>Snieder</surname> <given-names>H</given-names></name><name><surname>Wright</surname> <given-names>AF</given-names></name><name><surname>Rudan</surname> <given-names>I</given-names></name><name><surname>Boyer</surname> <given-names>LA</given-names></name><name><surname>Asselbergs</surname> <given-names>FW</given-names></name><name><surname>van Veldhuisen</surname> <given-names>DJ</given-names></name><name><surname>Stricker</surname> <given-names>BH</given-names></name><name><surname>Psaty</surname> <given-names>BM</given-names></name><name><surname>Ciullo</surname> <given-names>M</given-names></name><name><surname>Sanna</surname> <given-names>S</given-names></name><name><surname>Lehtimäki</surname> <given-names>T</given-names></name><name><surname>Wilson</surname> <given-names>JF</given-names></name><name><surname>Bandinelli</surname> <given-names>S</given-names></name><name><surname>Alonso</surname> <given-names>A</given-names></name><name><surname>Gasparini</surname> <given-names>P</given-names></name><name><surname>Jukema</surname> <given-names>JW</given-names></name><name><surname>Kääb</surname> <given-names>S</given-names></name><name><surname>Gudnason</surname> <given-names>V</given-names></name><name><surname>Felix</surname> <given-names>SB</given-names></name><name><surname>Heckbert</surname> <given-names>SR</given-names></name><name><surname>de Boer</surname> <given-names>RA</given-names></name><name><surname>Newton-Cheh</surname> <given-names>C</given-names></name><name><surname>Hicks</surname> <given-names>AA</given-names></name><name><surname>Chambers</surname> <given-names>JC</given-names></name><name><surname>Jamshidi</surname> <given-names>Y</given-names></name><name><surname>Visel</surname> <given-names>A</given-names></name><name><surname>Christoffels</surname> <given-names>VM</given-names></name><name><surname>Isaacs</surname> <given-names>A</given-names></name><name><surname>Samani</surname> <given-names>NJ</given-names></name><name><surname>de Bakker</surname> <given-names>PIW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>52 genetic loci influencing myocardial Mass</article-title><source>Journal of the American College of Cardiology</source><volume>68</volume><fpage>1435</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2016.07.729</pub-id><pub-id pub-id-type="pmid">27659466</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vissers</surname> <given-names>L</given-names></name><name><surname>Kalvakuri</surname> <given-names>S</given-names></name><name><surname>de Boer</surname> <given-names>E</given-names></name><name><surname>Geuer</surname> <given-names>S</given-names></name><name><surname>Oud</surname> <given-names>M</given-names></name><name><surname>van Outersterp</surname> <given-names>I</given-names></name><name><surname>Kwint</surname> <given-names>M</given-names></name><name><surname>Witmond</surname> <given-names>M</given-names></name><name><surname>Kersten</surname> <given-names>S</given-names></name><name><surname>Polla</surname> <given-names>DL</given-names></name><name><surname>Weijers</surname> <given-names>D</given-names></name><name><surname>Begtrup</surname> <given-names>A</given-names></name><name><surname>McWalter</surname> <given-names>K</given-names></name><name><surname>Ruiz</surname> <given-names>A</given-names></name><name><surname>Gabau</surname> <given-names>E</given-names></name><name><surname>Morton</surname> <given-names>JEV</given-names></name><name><surname>Griffith</surname> <given-names>C</given-names></name><name><surname>Weiss</surname> <given-names>K</given-names></name><name><surname>Gamble</surname> <given-names>C</given-names></name><name><surname>Bartley</surname> <given-names>J</given-names></name><name><surname>Vernon</surname> <given-names>HJ</given-names></name><name><surname>Brunet</surname> <given-names>K</given-names></name><name><surname>Ruivenkamp</surname> <given-names>C</given-names></name><name><surname>Kant</surname> <given-names>SG</given-names></name><name><surname>Kruszka</surname> <given-names>P</given-names></name><name><surname>Larson</surname> <given-names>A</given-names></name><name><surname>Afenjar</surname> <given-names>A</given-names></name><name><surname>Billette de Villemeur</surname> <given-names>T</given-names></name><name><surname>Nugent</surname> <given-names>K</given-names></name><name><surname>Raymond</surname> <given-names>FL</given-names></name><name><surname>Venselaar</surname> <given-names>H</given-names></name><name><surname>Demurger</surname> <given-names>F</given-names></name><name><surname>Soler-Alfonso</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Bhoj</surname> <given-names>E</given-names></name><name><surname>Hayes</surname> <given-names>I</given-names></name><name><surname>Hamilton</surname> <given-names>NP</given-names></name><name><surname>Ahmad</surname> <given-names>A</given-names></name><name><surname>Fisher</surname> <given-names>R</given-names></name><name><surname>van den Born</surname> <given-names>M</given-names></name><name><surname>Willems</surname> <given-names>M</given-names></name><name><surname>Sorlin</surname> <given-names>A</given-names></name><name><surname>Delanne</surname> <given-names>J</given-names></name><name><surname>Moutton</surname> <given-names>S</given-names></name><name><surname>Christophe</surname> <given-names>P</given-names></name><name><surname>Mau-Them</surname> <given-names>FT</given-names></name><name><surname>Vitobello</surname> <given-names>A</given-names></name><name><surname>Goel</surname> <given-names>H</given-names></name><name><surname>Massingham</surname> <given-names>L</given-names></name><name><surname>Phornphutkul</surname> <given-names>C</given-names></name><name><surname>Schwab</surname> <given-names>J</given-names></name><name><surname>Keren</surname> <given-names>B</given-names></name><name><surname>Charles</surname> <given-names>P</given-names></name><name><surname>Vreeburg</surname> <given-names>M</given-names></name><name><surname>De Simone</surname> <given-names>L</given-names></name><name><surname>Hoganson</surname> <given-names>G</given-names></name><name><surname>Iascone</surname> <given-names>M</given-names></name><name><surname>Milani</surname> <given-names>D</given-names></name><name><surname>Evenepoel</surname> <given-names>L</given-names></name><name><surname>Revencu</surname> <given-names>N</given-names></name><name><surname>Ward</surname> <given-names>DI</given-names></name><name><surname>Burns</surname> <given-names>K</given-names></name><name><surname>Krantz</surname> <given-names>I</given-names></name><name><surname>Raible</surname> <given-names>SE</given-names></name><name><surname>Murrell</surname> <given-names>JR</given-names></name><name><surname>Wood</surname> <given-names>K</given-names></name><name><surname>Cho</surname> <given-names>MT</given-names></name><name><surname>van Bokhoven</surname> <given-names>H</given-names></name><name><surname>Muenke</surname> <given-names>M</given-names></name><name><surname>Kleefstra</surname> <given-names>T</given-names></name><name><surname>Bodmer</surname> <given-names>R</given-names></name><name><surname>de Brouwer</surname> <given-names>APM</given-names></name><collab>DDD Study</collab></person-group><year iso-8601-date="2020">2020</year><article-title>De novo variants in CNOT1, a central component of the CCR4-NOT complex involved in gene expression and RNA and protein stability, cause neurodevelopmental delay</article-title><source>The American Journal of Human Genetics</source><volume>107</volume><fpage>164</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2020.05.017</pub-id><pub-id pub-id-type="pmid">32553196</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Westerfield</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1993">1993</year><source>The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (Brachy Danio rerio)</source><publisher-name>University of Oregon Press</publisher-name></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yagi</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Gabriel</surname> <given-names>GC</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Peterson</surname> <given-names>K</given-names></name><name><surname>Murray</surname> <given-names>SA</given-names></name><name><surname>Aronow</surname> <given-names>BJ</given-names></name><name><surname>Martin</surname> <given-names>LJ</given-names></name><name><surname>Benson</surname> <given-names>DW</given-names></name><name><surname>Lo</surname> <given-names>CW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The genetic landscape of hypoplastic left heart syndrome</article-title><source>Pediatric Cardiology</source><volume>39</volume><fpage>1069</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1007/s00246-018-1861-4</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname> <given-names>XX</given-names></name><name><surname>Yelon</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cadm4 restricts the production of cardiac outflow tract progenitor cells</article-title><source>Cell Reports</source><volume>7</volume><fpage>951</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.04.013</pub-id><pub-id pub-id-type="pmid">24813897</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.59554.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Ebert</surname><given-names>Antje</given-names></name><role>Reviewing Editor</role><aff><institution>Department of Cardiology and Pneumology, University Medical Center Göttingen</institution><country>Germany</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Kochilas</surname><given-names>Lazaros</given-names> </name><role>Reviewer</role></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This paper describes a new method platform to facilitate understanding of the molecular basis of complex heart diseases. Employing a combined analysis of human, zebrafish, and Drosophila model systems, this study identifies and characterizes an exemplary genetic variant relevant to the development of Hypoplastic Left Heart Syndrome (HLHS). Use of this technological tool could facilitate future basic as well as translational research on the development of heart diseases.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Patient-specific functional genomics and disease modeling suggest a role for <italic>LRP2</italic> in hypoplastic left heart syndrome&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Didier Stainier as the Senior Editor. The reviewers have discussed the reviews with one another, and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in <italic>eLife</italic> but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.</p><p>Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in <italic>eLife</italic>, either of which would be linked to the original paper.</p><p>Summary:</p><p>Hypoplastic Left Heart Syndrom (HLHS) is a severe congenital heart disease which remains genetically incompletely understood. The authors use a cross-functional genetic approach and a combination of <italic>Drosophila</italic>, zebrafish, and human iPSC model systems to identify novel genetic elements that underlie HLHS. The authors selected a variant in LDL receptor related protein 2 (<italic>LRP2</italic>) identified from a sporadic HLHS proband-parent trio to examine contribution of this gene defect to HLHS disease phenotypes. WGS data were filtered for rare de-novo, recessive and loss-of-function variants in candidate genes prior to functional evaluation. Three different model systems were utilized to evaluate dysregulations in the presence of the selected <italic>LRP2</italic> variant in context of HLHS. This integrated analysis is powerful and could indeed help in identifying and assessing genetic determinants of human disorders.</p><p>The authors suggest a model in which Wnt and Shh-mediated signaling impairs cardiomyocyte proliferation in HLHS. New evidence provided to support this model is scarce; the mechanisms of FZD10/PTCH1-dependent effects on <italic>LRP2</italic> are not sufficiently substantiated. Also, there are concerns regarding assessment of the cardiomyocyte proliferation defect.</p><p>Overall, this manuscript addresses a topic of interest with state of the art methodology and represents a valuable tool and resource. As a resource platform, this tool could be of broader use to researchers in the field. We have the following suggestions to improve the manuscript.</p><p>Essential revisions:</p><p>1) To lock in mechanistic evidence for the proposed model would require substantial new experimental data. On the other hand, the integrated approach employed in this manuscript contributes merit as a resource platform. To be considered as a tool and resource, conclusions should be adapted to reflect that the novel contribution of this paper is a technological platform which may identify novel variant mutations in genetic disorders such as HLHS. Claims on the presented network model as a mechanistic basis, as well as on causality of the <italic>LRP2</italic> variant should be removed or reduced. The authors should especially re-consider the context of the existing <italic>LRP2</italic> mutant mouse model (Baardman et al., 2016) which displays a left-ventricular non-compaction phenotype. Moreover, the authors should discuss how their experimental pipeline could be extended to better assess causality of the <italic>LRP2</italic> variant.</p><p>2) Experiments addressing the function of <italic>LRP2</italic> as an HLHS candidate gene using adult Drosophila hearts are not convincing, as postmitotic cardiac cells will limit an assessment of proliferation defects. The effect of <italic>LRP2</italic> on cardiac cell proliferation should be better documented. For example, testing candidate gene function on cardioblast formation during heart development in Drosophila embryos or, alternatively, zebrafish embryos could be more informative.</p><p>3) The title should indicate this work to cover a cross-species genomics method platform rather than disease modeling.</p><p>Revisions expected in follow-up work:</p><p>1) A causal link that the <italic>LRP2</italic> variant mutation critically contributes to HLHS disease phenotypes should be provided, using an <italic>LRP2</italic> variant Drosophila or zebrafish line, or mutation-correction in patient-specific iPSCs.</p><p>2) Experiments should be performed to demonstrate how <italic>LRP2</italic> regulates cell cycle and cardiomyocyte proliferation via Wnt/Shh-dependent signaling. Can a direct <italic>LRP2</italic>-dependent regulation of FZD10/PTCH1 be confirmed e.g. in interaction studies? To support modulation by Wnt agonists/Shh antagonists in presence of the <italic>LRP2</italic> variant, additional regulators of these pathways should be as assessed. The zebrafish model (CRISPR <italic>lrp2a</italic> mutants) or an <italic>LRP2</italic> variant Drosophila line could be used for this together with siRNAs or CRISPR for knock-down/ knockout, targeting <italic>LRP2</italic>.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.59554.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in eLife but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.</p></disp-quote><p>We thank the reviewers and editors for their positive evaluation of our work. As requested, we have revised the manuscript to limit claims the reviewers deemed insufficiently supported by our data, and where appropriate, we have explicitly stated that additional lines of evidence are needed. Below, we summarized the planned additional experiments over the next months (COVID-19 situation permitting) that we hope will provide additional data in support of our conclusions.</p><disp-quote content-type="editor-comment"><p>Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in eLife, either of which would be linked to the original paper.</p></disp-quote><p>Summary of ‘additional experiments’ that are planned (resulting data are intended to be reported in a self-standing document submitted to Research Advance in <italic>eLife</italic>, and/or uploaded to the BioRxiv server, and linked to the original paper):</p><p>– Genetic interaction studies between <italic>LRP2/mgl</italic> and component of SHH/WNT pathways in <italic>Drosophila,</italic> hiPSC-CM, and best subset in zebrafish</p><p>– Experiment addressing <italic>LRP2</italic> effect on proliferation: We will use zebrafish to examine loss function of <italic>lrp2a</italic> (and key potential interactors) on proliferation in EdU incorporation assays.</p><disp-quote content-type="editor-comment"><p>Summary:</p><p>Hypoplastic Left Heart Syndrom (HLHS) is a severe congenital heart disease which remains genetically incompletely understood. The authors use a cross-functional genetic approach and a combination of Drosophila, zebrafish, and human iPSC model systems to identify novel genetic elements that underlie HLHS. The authors selected a variant in LDL receptor related protein 2 (LRP2) identified from a sporadic HLHS proband-parent trio to examine contribution of this gene defect to HLHS disease phenotypes. Whole-genome sequencing data were filtered for rare de-novo, recessive and loss-of-function variants in candidate genes prior to functional evaluation. Three different model systems were utilized to evaluate dysregulations in the presence of the selected LRP2 variant in context of HLHS. This integrated analysis is powerful and could indeed help in identifying and assessing genetic determinants of human disorders.</p></disp-quote><p>We thank the reviewers for their appreciation of our integrated analysis platform for assessing the cardiac role of HLHS disease gene candidates. We have further stressed the novelty of our synergistic approaches in gene discovery and toned-down conclusions relating to HLHS disease mechanisms (see text changes in track throughout the revised manuscript).</p><disp-quote content-type="editor-comment"><p>The authors suggest a model in which Wnt and Shh-mediated signaling impairs cardiomyocyte proliferation in HLHS. New evidence provided to support this model is scarce; the mechanisms of FZD10/PTCH1-dependent effects on LRP2 are not sufficiently substantiated. Also, there are concerns regarding assessment of the cardiomyocyte proliferation defect.</p></disp-quote><p>We appreciate this criticism. We will perform genetic interaction studies in our model systems to further evaluate a <italic>LRP2</italic>/<italic>mgl</italic>-Shh/Wnt connection, and further assess CM proliferation in zebrafish.</p><p>– Genetic interactions between <italic>LRP2</italic> and WNT/SHH components in iPSC-CMs: In Figure 4D-G of the manuscript, we reported KD of <italic>LRP2</italic> in combination with PTCH1 using siRNA, and <italic>LRP2</italic> KD in combination with the WNT activator drug ‘BIO’. To further test LRP2-WNT/SHH interactions, we will use siRNAs for additional Wnt/Shh pathway genes in hiPSC-CMs treated with siLRP2 alone and in combination of the other siRNAs (EdU incorporation assay).</p><p>– Genetic interactions between <italic>mgl</italic>/<italic>LRP2</italic> and <italic>wg/hh</italic> pathway components in Drosophila embryonic cardioblasts and adult heart function: To examine the effects of genetic interactions on embryonic cardioblasts, we will use early mesodermal and cardioblast drivers (e.g. <italic>Mef2</italic>-Gal4, <italic>TinD</italic>-Gal4, resp.) to KD <italic>wg/hh</italic> components in a <italic>mgl</italic> mutant and mid-cardioblast marked background (<italic>mgl/Y;</italic>Gal4<italic>&gt;hh/wg-RNAi,mid-GFP</italic> – see Schroeder et al., 2019) – also an aim in a submitted grant proposal). Various antibodies will be used to determine abnormalities in subsequently fixed embryos. To examine interaction in adult hearts, we will KD <italic>mgl</italic> and interactor in the heart throughout life (e.g. <italic>Hand<sup>4.2</sup></italic>-Gal4&gt;<italic>hh/wg-RNAi,tdtK-RFP</italic>) and determine functional and structural defects. We have evaluated 800+ genes in a year using this platform.</p><p>– Genetic interactions between <italic>LRP2</italic> and Wnt/Shh components in zebrafish: Best interactors in hiPSC-CM proliferation assay and embryonic and adult fly heart assays will be tested in zebrafish first using co-injection of subthreshold doses of MO against <italic>lrp2a</italic> combined with MO of potential interactors. Interactions will then be also confirmed with CRISPR generated <italic>lrp2a</italic> mutants.</p><p>– The impact of LRP2 on proliferation will be further investigated zebrafish <italic>lrp2a</italic> morphants and CRISPR mutants, by proliferation analysis using EdU incorporation and in cell death assays.</p><disp-quote content-type="editor-comment"><p>Overall, this manuscript addresses a topic of interest with state of the art methodology and represents a valuable tool and resource. As a resource platform, this tool could be of broader use to researchers in the field. We have the following suggestions to improve the manuscript.</p><p>Essential revisions:</p><p>1) To lock in mechanistic evidence for the proposed model would require substantial new experimental data. On the other hand, the integrated approach employed in this manuscript contributes merit as a resource platform. To be considered as a tool and resource, conclusions should be adapted to reflect that the novel contribution of this paper is a technological platform which may identify novel variant mutations in genetic disorders such as HLHS. Claims on the presented network model as a mechanistic basis, as well as on causality of the LRP2 variant should be removed or reduced.</p></disp-quote><p>We agree, this paper described a novel integrated platform for evaluation heart disease candidates (e.g. from genomics and transcriptomics analysis of heart disease patients) and potential disease-relevant genetic interactions. We have toned down the conclusions that claim causality of <italic>LRP2</italic> in HLHS, such as identified <italic>LRP2</italic> variants contributing to the disease – see extensive track changes throughout the manuscript.</p><disp-quote content-type="editor-comment"><p>The authors should especially re-consider the context of the existing LRP2 mutant mouse model (Baardman et al., 2016) which displays a left-ventricular non-compaction phenotype.</p></disp-quote><p>The reviewer implies that the <italic>LRP2</italic> mutant mouse model yields solely a LVNC phenotype. Yet, on further inspection of Baardman et al. (Baardman et al., 2016), mice develop LVNC and CHDs. In the second paragraph of the subsection “Integrated multidisciplinary disease gene discovery platform”, we now discuss the possibility that <italic>LRP2</italic> could contribute to several CHDs, involving not just proliferation but also proper differentiation, such as LVNC). Of note, it is well known that core cardiogenic genes, like <italic>NKX2-5</italic>, are likely involved in several CHDs.</p><disp-quote content-type="editor-comment"><p>Moreover, the authors should discuss how their experimental pipeline could be extended to better assess causality of the LRP2 variant.</p></disp-quote><p>We also discuss in more detail (e.g. in the last paragraph of the subsection “Integrated multidisciplinary disease gene discovery platform”) how the pipeline could be used to further explore causality, such as stated below under Follow-up Work (2.).</p><disp-quote content-type="editor-comment"><p>2) Experiments addressing the function of LRP2 as an HLHS candidate gene using adult Drosophila hearts are not convincing, as postmitotic cardiac cells will limit an assessment of proliferation defects. The effect of LRP2 on cardiac cell proliferation should be better documented. For example, testing candidate gene function on cardioblast formation during heart development in Drosophila embryos or, alternatively, zebrafish embryos could be more informative.</p></disp-quote><p><italic>Drosophila</italic> hearts not easily amenable to assay the role of genes in cardiomyocyte proliferation, since proliferation of cardioblasts is complete very early, before heart tube assembly. Rather, the embryonic heart is best used for determining cardiac cell specification, differentiation, and eventually establishment of robust cardiac function, the latter being a major concern in adult CHD. Complementary, as stated above for the genetic interaction experiments, we will also use cell-type specific markers to assess cardiac specification of the embryonic fly heart. Further, we will use zebrafish to better document <italic>LRP2</italic>’s role on cardiac cell proliferation (EdU incorporation).</p><disp-quote content-type="editor-comment"><p>3) The title should indicate this work to cover a cross-species genomics method platform rather than disease modeling.</p></disp-quote><p>We agree that it was not our intent to perform disease-proximal modeling, but rather perform a genetic evaluation of candidate genes using our integrated platform. We propose to change the title to &quot;Patient-specific genomics and cross-species functional analysis implicate a role for <italic>LRP2</italic> in hypoplastic left heart syndrome&quot;.</p><disp-quote content-type="editor-comment"><p>Revisions expected in follow-up work:</p><p>1) A causal link that the LRP2 variant mutation critically contributes to HLHS disease phenotypes should be provided, using an LRP2 variant Drosophila or zebrafish line, or mutation-correction in patient-specific iPSCs.</p><p>2) Experiments should be performed to demonstrate how LRP2 regulates cell cycle and cardiomyocyte proliferation via Wnt/Shh-dependent signaling. Can a direct LRP2-dependent regulation of FZD10/PTCH1 be confirmed e.g. in interaction studies? To support modulation by Wnt agonists/Shh antagonists in presence of the LRP2 variant, additional regulators of these pathways should be as assessed. The zebrafish model (CRISPR lrp2a mutants) or an LRP2 variant Drosophila line could be used for this together with siRNAs or CRISPR for knock-down/ knockout, targeting LRP2.</p></disp-quote><p>We thank the reviewers for these suggestions. In fact, this is exactly what we have in mind in long-term follow-up studies. We have submitted an R01 grant proposal to NIH on 1) generating <italic>LRP2</italic> variants in our models and proliferation rescue by CRISPR/Cas9 correction of patient-derived iPSCs; and on 2) LRP2 regulating cell proliferation in cooperation with Wnt/Shh by genetic interaction studies, as well as other candidate genes with patient-specific rare, predicted-damaging variants prioritized in other HLHS family trios. These experiments, however, are a longer-term goal, requiring significant resources and efforts.</p></body></sub-article></article>